Section |
Name |
Details |
02.06.02 |
|
|
03.01.03 |
|
Prescribe by brand name |
05.03.05 |
Ribavirin |
Chronic hepatitis C in line with the recommendations in NICE TA 75, TA 106 and TA 200. Hepatitis C in children and young people 3-17 NICE TA 300 |
06.01.01.03 |
4SURE |
|
05.03.01 |
Abacavir Ziagen® |
HIV infection only |
05.03.01 |
Abacavir and Lamivudine Kivexa® |
HIV infection only |
05.03.01 |
Abacavir and Lamivudine and Zidovudine Trizivir® |
HIV infection only |
10.01.03 |
Abatacept |
Infusion and subcutaneous injection |
08.01.05 |
Abemaciclib Verzenios® |
|
08.01.05 |
Abemaciclib Verzenios® |
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
08.03.04.02 |
Abiraterone Zytiga® |
|
04.10.01 |
Acamprosate Campral EC® |
Maintaining abstinence in alcohol dependence - refer to shared care guidelines |
06.01.02.03 |
Acarbose Glucobay® |
|
09.06.04 |
Accrete D3® |
Tablets can be swallowed whole or broken in half |
02.08.02 |
Acenocoumarol Sinthrome® |
|
11.06 |
Acetazolamide Diamox® |
Tablets
SR capsules |
12.01.01 |
Acetic acid 2% spray Earcalm ® |
|
20 |
Acetic Acid Solution 5% |
|
11.08.02 |
Acetylcholine Chloride Miochol-E® |
|
18 |
Acetylcysteine |
Paracetamol overdose |
20 |
ACETYLCYSTEINE |
|
11.08.01 |
Acetylcysteine 5% with Hypromellose 0.35% Ilube® |
|
03.07 |
Acetylcysteine injection |
Administered via nebuliser as a mucolytic - refer to PHT Drug Therapy Guideline 107.03 |
20 |
Acetylcysteine tablets |
|
05.03.02.01 |
Aciclovir |
|
05.03.02.01 |
Aciclovir |
|
13.10.03 |
Aciclovir 5% cream |
NHS England low value medication
A prescription for treatment of cold sores should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment
|
11.03.03 |
Aciclovir eye ointment 3% Zovirax® |
This product will be discontinued. GSK anticipate supplies to be available until June 2019.
A suitable alternative is ganciclovir eye gel |
01.01.02 |
Acidex Advance® |
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
02.12 |
Acipimox Olbetam® |
Information on restriction - Mixed dyslipidaemia unresponsive to statins and intolerant of fibrates
|
13.05.02 |
Acitretin Neotigason® |
|
03.01.02 |
Aclidinium Eklira Genuair® |
LAMA in multidose dry powder inhaler device. Refer to COPD guidelines |
03.01.04 |
Aclidinium and formoterol inhaler Duaklir Genuair ® |
LABA+LAMA. Refer to COPD guidelines |
19.23 |
Actico 10cm x 6m |
Cohesive short stretch bandage for single use and adapted according to ankle circumference. can be worn for up to 7 day. Recommended in patients with an ABPI of > 0.8
10cm width for routine below knee leg ulcer bandaging. |
19.23 |
Actico 12cm x 6m |
12cm Actico bandages are for use in patients with chronic oedema. 12 cm banadge should be applied to the thigh. |
19.23 |
Actico 8cm x 6m |
8cm Actico bandages are for use in patients with chronic oedema. 8 cm banadge should be applied to the foot. |
19.22 |
Acti-Glide Compression hosiery application system |
Supply of a single unit only |
13.08.01 |
Actikerall® Fluorouracil 0.5%/ salicylic acid 10% |
|
19.22 |
ActiLymph Class 1 18-21mmHg |
Light compression Hosiery for early mild chronic oedema with little leg distortion. suitable for chronic oedema, lymphoedema, lipoedema, prophylaxis, maintenence therapy and palliative use.
Available in Below knee and above knee. Wide or regular band. Closed toe and open toe. Various colours and sizes. |
19.22 |
ActiLymph Class 2 23-32mmHg |
Medium compression hosiery for moderate to severe chronic oedema and lymphoedema where resistant oedema occurs and shape disfunction.
Available in Below knee and above knee. Wide or regular band. Closed toe and open toe. Various colours and sizes. |
19.22 |
ActiLymph Class 3 34-46mmHg |
Provides strong compression and should be used for maintenance of severe chronic oedema and lymphoedema, where resistant oedema persists, history of recurring ulceration or where lymphatic damage is considerable and use of lower classes has proved ineffective.
Available in Below knee and above knee. Wide or regular band. Closed toe and open toe. Various colours and sizes. |
19.22 |
Activa Leg Ulcer Hosiery Kit 1 stocking, 2 liners |
Available as small, medium, large , XL, XXL. Useful for active ulceration to apply full compression for patients who can't tolerate bandaging. Assessing and measuring as per single hosiery product. |
19.22 |
Activa Liner pack (3 liners) |
Liner pack available in all sizes, both open and closed toe. |
19.22 |
Activa support compression hosiery Class 1 14-17mmHg |
Light (mild) compression Hosiery
Available in Below knee and thigh length, closed toe and open toe. Various colours and sizes. |
19.22 |
Activa support compression hosiery Class 2 18-24mmHg |
Medium (moderate) compression hosiery
Available in Below knee and thigh length, closed toe and open toe. Various colours and sizes. |
19.22 |
Activa support compression hosiery Class 3 25-35mmHg |
Strong support compression hosiery for recurring leg ulceration and gross varices.
Available in Below knee and thigh length, closed toe and open toe. Various colours and sizes. |
18 |
Activated charcoal |
Antidote for acute poisoning with various medicines/poisons |
01.05.03 |
Adalimumab Humira® Imraldi® Amgevita® |
Prescribe by brand name
Crohns Disease in line with NICE TA 187, moderately to severely active ulcerative colitis NICE TA 329 |
10.01.03 |
Adalimumab Imraldi ® Amgevita ® Humira ® |
|
11.04.02 |
Adalimumab injection Imraldi ® Amgevita ® Humira® |
|
13.05.03 |
Adalimumab injection Imraldi ® Amgevita ® Humira® |
|
13.06.01 |
Adapalene Differin® |
|
13.06.01 |
Adapalene / Benzoyl Peroxide Epiduo® |
|
09.06.04 |
Adcal-D3 Dissolve® |
For patients requiring a soluble preparation
Calcium carbonate 1500mg equivalent to 600mg of elemental calcium, Colecalciferol 400iu equivalent to 10μg vitamin D3 |
09.06.04 |
Adcal-D3® |
Note doses are different between chewable tablets and caplets
|
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
Chronic hepatitis B in line with NICE TA 96 |
02.03.02 |
Adenosine |
|
08.02.02 |
Adoport® Tacrolimus |
RED for Renal transplant patients |
03.04.03 |
Adrenaline (epinephrine) 1 in 10,000 (dilute) |
|
03.04.03 |
Adrenaline (epinephrine) 1 in 1000 injection |
|
03.04.03 |
Adrenaline (epinephrine) injection |
Self-administered for anaphylaxis
Emerade, EpiPen, Jext
Prescribe by brand name. |
02.07.03 |
Adrenaline / Epinephrine 1 in 10,000 (dilute) injection |
|
11.05 |
Adrenaline 0.1% preservative free |
|
08.02.02 |
Advagraf® Tacrolimus |
RED for Renal transplant patients |
03.01.05 |
AeroChamber Plus® |
|
08.01.05 |
Afatinib Giotrif® |
|
11.08.02 |
Aflibercept Eylea® |
|
04.03.04 |
Agomelatine Valdoxan® |
Refer to mental health provider guidelines |
20 |
Ajmaline injection |
Consultant cardiologist only for diagnosis of Brugada syndrome |
13.11.01 |
Alcohol impregnated swabs Sterets |
|
08.01.05 |
Alectinib Alecensa® |
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
06.06.02 |
Alendronic Acid Tablets 70mg |
|
09.06.04 |
Alfacalcidol |
|
15.01.04.03 |
Alfentanil |
|
10.03.02 |
Algesal |
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
03.04.01 |
Alimemazine |
Only as an option for use in paediatric patients requiring sedation for procedures |
02.12 |
Alirocumab Praluent® |
Primary hypercholesterolaemia or mixed dyslipidaemia |
13.05.01 |
Alitretinoin Toctino® |
NOTE 10mg and 30mg capsules are the SAME PRICE (£411) per pack of 30 capsules.
Do not dispense 3 x 10mg capsules if a patient is on 30mg (standard) dose. |
19.11 |
Allevyn Life 12.9cm x 12.9cm |
Hyper-absorbent. For use on high exudating wounds where a wear time 5 - 7 days is required. |
19.11 |
Allevyn Life 15.4cm x 15.4cm |
Hyper-absorbent. For use on high exudating wounds where a wear time 5 - 7 days is required. |
10.01.04 |
Allopurinol |
|
06.01.02.03 |
Alogliptin Vipidia▼® |
First choice DPP-4 inhibitor for new initiations |
09.06.05 |
Alpha Tocopheryl Acetate |
|
13.09 |
Alphosyl 2 in 1® shampoo Alcoholic coal tar extract 5% |
|
07.01.01.01 |
Alprostadil Prostin VR® |
Information on restriction - Neonatal unit only
|
07.04.05 |
Alprostadil Caverject |
SLS endorsement required in primary care
Training on use must be given in secondary care
|
07.04.05 |
Alprostadil Viridal® Duo |
Viridal Duo is used if Caverject is not available |
07.04.05 |
Alprostadil 3mg/g cream Vitaros® |
SLS endorsement required in primary care |
02.10.02 |
Alteplase Actilyse® |
For Pulmonary embolism and acute ischemic stroke. |
11.99.99.99 |
Alteplase intravitreal injection |
Submacular haemorrhage - unlicensed |
13.12 |
Aluminimum chloride hexahydrate Anhydrol Forte® |
Aluminium chloride hexahydrate 20% in an alcoholic basis
NHS England low value medication
A prescription for high strength antiperspirants for the treatment of mild to moderate hyperhidrosis should not routinely be offered in primary care as the condition is appropriate for self-care |
13.12 |
Aluminimum chloride hexahydrate Driclor® |
Aluminimum chloride hexahydrate 20% in an alcoholic basis
NHS England low value medication
A prescription for high strength antiperspirants for the treatment of mild to moderate hyperhidrosis should not routinely be offered in primary care as the condition is appropriate for self-care |
09.05.02.02 |
Aluminium Hydroxide Alu-Cap® |
|
01.01.01 |
Aluminium Only Preparations Alu-Cap® |
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
04.09.01 |
Amantadine |
Includes capsules and syrup |
05.01.04 |
Amikacin |
On microbiology advice only
100mg in 2ml injection |
11.03.01 |
Amikacin 2.5% eye drops |
Unlicensed |
02.02.03 |
Amiloride Hydrochloride |
|
03.01.03 |
Aminophylline Phyllocontin Continus® |
Prescribe by brand name |
03.01.03 |
Aminophylline injection |
|
02.03.02 |
Amiodarone |
Suspension 50mg in 5ml - unlicensed special (paediatrics only) |
02.03.02 |
Amiodarone |
|
04.02.01 |
Amisulpride |
|
04.03.01 |
Amitriptyline |
|
04.07.03 |
Amitriptyline |
|
04.07.04.02 |
Amitriptyline |
|
02.06.02 |
Amlodipine |
|
05.01.01.03 |
Amoxicillin |
|
05.02 |
Amphotericin Fungizone® |
|
05.02 |
Amphotericin AmBisome® |
|
11.03.02 |
Amphotericin 0.15% |
Unlicensed - Ophthalmology only |
09.01.04 |
Anagrelide Xagrid® |
|
10.01.03 |
Anakinra Kineret® |
|
08.03.04.01 |
Anastrozole |
|
12.03.01 |
Antacid with Oxetacaine |
unlicensed - Refer to mouthcare guidelines
|
11.04.02 |
Antazoline 0.5% with xylometazoline 0.05% Otrivine-Antistin® |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
14.05.03 |
Anti-D (Rh0) Immunoglobulin |
|
08.02.02 |
Antithymocyte immunoglobulin (rabbit) Thymoglobuline® |
|
01.07.01 |
Anusol |
Includes ointment and suppositories
NHS England low value medicine
A prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
01.07.02 |
Anusol-HC |
Includes ointment and suppositories
NHS England low value medicine
A prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
02.08.02 |
Apixaban Eliquis® |
VTE prophylaxis following elective hip and knee replacement (full course to be supplied by hospital)
Stroke prevention in non-valvular AF
DVT and PE treatment and secondary prevention |
04.09.01 |
Apomorphine |
Consultant only - requires specialist initiation and supervision |
11.08.02 |
Apraclonidine Iopidine® |
Apraclonidine 0.5% eye drops - short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery.
Apraclonidine 1% single dose - to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. |
13.05.03 |
Apremilast Otezla® |
|
04.06 |
Aprepitant Emend® |
NHSE funded chemotherapy supportive drug
PONV following bariatric surgery (off-license) |
13.02.01 |
AproDerm Colloidal Oat Cream® |
Cost effective alternative to Aveeno cream |
A2.01 |
Aptamil Pepti 1 and 2 |
|
A2.01 |
Aptamil Pepti 1® |
Pepti 1 and 2 - for Cows Milk Protein Allergy
Extensively Hydrolysed Formula
First line agent |
A2.01 |
Aptamil Pepti Junior® |
On the advice of secondary care only
Cows Milk Allergy and malabsorption |
13.02.01 |
Aquamol® cream |
Can be used as a soap substitute |
13.02.01 |
Aqueous Cream BP |
ZeroAQS is the lower cost alternative for prescribing in primary care. |
01.06.03 |
Arachis Oil |
|
02.08.01 |
Argatroban Exembol® |
Under advice of haematology only. |
04.02.01 |
Aripiprazole Abilify |
As per SHFT and Solent rapid tranquilization guidance only |
04.02.01 |
Aripiprazole |
First line if hyperprolactinaemia caused by other agents. Schizophrenia in 15-17 year olds (second line) NICE TA 213. Manic episodes in bipolar disorder in adolescents over 13 NICE TA 292 |
04.02.02 |
Aripiprazole Abilify Maintena® |
Southern Health NHS FT and Solent NHS Trust psychiatrists only |
08.01.05 |
Arsenic Trioxide Trisenox® |
|
05.04.01 |
Artemether with lumefantrine Riamet® |
|
20 |
Artesunate injection |
Falciparum malaria - refer to PHT Adult Antimicrobial Guide |
15.02 |
Articaine Hydrochloride with Adrenaline Septanest® |
|
12.03.05 |
AS Saliva Orthana® spray |
|
09.06.03 |
Ascorbic Acid Vitamin C |
NHS England low value medication
For medically diagnosed eficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption. |
20 |
Asparaginase (Medac) Injection 10000 units |
|
04.07.01 |
Aspirin |
Mild to moderate pain
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
10.01.01 |
Aspirin 300mg |
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
02.09 |
Aspirin (antiplatelet) |
|
05.03.01 |
Atazanavir sulfate and cobicistat Evotaz® |
HIV infection only |
02.04 |
Atenolol |
|
08.01.05 |
Atezolizumab Tecentriq® |
|
04.04 |
Atomoxetine Strattera® |
Children - CAMHS initiation only
CAMHS Shared care agreement for Hampshire will be available on iDOCs
Adults - diagnosis and treatment initiation via Hampshire ADHD service (provided by Surrey and Borders Partnership NHSFT)
Awaiting shared care guidelines |
02.12 |
Atorvastatin |
Prescribe generically, avoid chewable tablets |
15.01.05 |
Atracurium Besilate |
|
19.01 |
Atrauman 10cm x 20cm |
May not be suitable for patients with sensitivities to conconut or its derivatives. Consider Tricotex for patients with coconut allergy.
|
19.01 |
Atrauman 20cm x 30cm |
May not be suitable for patients with sensitivities to conconut or its derivatives. Consider Tricotex for patients with coconut allergy. |
19.01 |
Atrauman 5cm x 5cm |
May not be suitable for patients with sensitivities to conconut or its derivatives. Consider Tricotex for patients with coconut allergy. |
19.01 |
Atrauman 7.5cm x 10cm |
May not be suitable for patients with sensitivities to conconut or its derivatives. Consider Tricotex for patients with coconut allergy. |
15.01.03 |
Atropine minijet® |
Secondary Care only Except for Emergency use |
18 |
Atropine |
Poisoning by organophosphorus or carbamate insecticides |
11.05 |
Atropine 1% eye drops and unit dose eye drops |
|
15.01.03 |
Atropine sulfate |
|
07.04.05 |
Avanafil |
Second line for erectile dysfuntion
SLS endorsement required in primary care |
09.01.04 |
Avatrombopag Doptelet® |
|
13.02.01 |
Aveeno® cream |
Zeroveen is the lower cost alternative for prescribing in primary care. |
08.01.05 |
Avelumab Bavencio® |
|
06.01.06 |
Aviva Test Strip® |
Category 2 |
08.01.05 |
Axicabtagene ciloleucel YESCARTA® |
|
08.01.05 |
Axitinib Inlyta® |
|
A2.02.01.02 |
AYMES Shake |
First choice if food fortification is not sufficient
Use Aymes powder for care home patients and those with carers
USe Aymes complete for patients with no-one to make up the shake |
08.01.03 |
Azacitidine Vidaza® |
|
08.02.01 |
Azathioprine |
|
01.05.03 |
Azathioprine tablets |
|
01.05.03 |
Azathioprine tablets |
|
10.01.03 |
Azathioprine tablets |
|
13.05.03 |
Azathioprine tablets |
unlicensed
|
13.06.01 |
Azelaic Acid Finacae® |
|
12.02.01 |
Azelastine and fluticasone nasal spray Dymista® |
Allergic Rhinitis, not first-line.
Only for patients requiring combination treatment with both agents to control symptoms. |
12.02.01 |
Azelastine hydrochloride nasal spray |
|
05.01.05 |
Azithromycin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
05.01.05 |
Azithromycin |
Shared care for long-term prophylaxis in COPD and bronchiectasis only |
11.03.01 |
Azithromycin Azyter® |
|
05.01.02.03 |
Aztreonam Azactam® |
On microbiology advice only |
05.01.02.03 |
Aztreonam nebuliser solution Cayston® |
For cystic fibrosis only in accordance with NHSE policy A01/P/b |
04.07.03 |
Baclofen |
|
10.02.02 |
Baclofen |
|
11.08.02 |
Balanced salt solution |
|
13.02.01 |
Balneum® cream |
Contains 5% urea - for dry skin conditions |
13.02.01 |
Balneum® Plus cream |
Contains 5% urea and lauromacrogols. For dry, scaling and itching skin |
01.05.01 |
Balsalazide sodium capsules Colazide® |
Only for patients intolerant of all mesalazine products. Initiation by consultant gastroenterologist only |
10.01.03 |
Baricitinib tablets Olumiant® |
|
08.02.02 |
Basiliximab Simulect® |
|
08.02.04 |
BCG bladder instillation OncoTICE® |
|
08.02.04 |
BCG bladder instillation ImmuCyst® |
|
14.04 |
BCG vaccine diagnostic agent |
|
14.04 |
BCG vaccine Intradermal |
For use in at risk groups only (newborn infants of parents from high risk areas and those resident in or originating from high incidence areas)
None of the local CCGs meet the criterion for a high incidence area. |
06.01.01.03 |
BD Viva |
|
03.02 |
Beclometasone Kelhale® |
Prescribe by BRAND name
Cost effective alternative to QVAR inhaler - only available as MDI |
03.02 |
Beclometasone Qvar® |
MDI / Autohaler / Easi-Breathe
Prescribe by BRAND NAME - Kelhale is a cost effective alternative for patients requiring a MDI |
03.02 |
Beclometasone Clenil Modulite® |
Prescribe by BRAND NAME - CFC-free beclometasone inhalers are NOT interchangeable |
03.02 |
Beclometasone and formoterol Fostair® |
MDI and NEXThaler
Asthma Step 3 BTS guidelines for adults over 18, COPD – refer to local guidelines |
03.02 |
Beclometasone Clickhaler Asmabec |
Dry powder |
20 |
Beclometasone dipropionate 0.0025% w/w in WSP BP ointment |
Unlicensed special listed on BAD specials list 2018 |
12.02.01 |
Beclometasone dipropionate nasal spray |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
01.05.02 |
Beclometasone m/r tablets Clipper® |
Mild to moderate ulcerative colitis in active phase - full course to be supplied by hospital |
10.01.03 |
Belimumab Benlysta® |
|
08.01.01 |
Bendamustine Levact® |
For indications and criteria for CDF funding refer to CDF list. |
02.02.01 |
Bendroflumethiazide |
|
04.02.01 |
Benperidol Anquil® |
Psychiatry only
Note HIGH COST in primary care |
03.04.02 |
Benralizumab Fasenra® |
|
05.01.01 |
Benzathine penicillin |
For use within Solent Sexual Health Service Only |
20 |
Benzbromarone 100mg tablets |
Gout - consultant rheumatologist only |
20 |
Benzoin Tincture, Compound, BP |
|
13.06.01 |
Benzoyl Peroxide PanOxyl® |
Aquagel (aqueous gel) 2.5%, 5%, 10%
Cream 5%
Gel 10%
Wash 10% |
13.06.01 |
Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily |
|
12.03.01 |
Benzydamine Difflam® |
NHS England low value medicine
A prescription for treatment of acute sore throat should not be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
13.10.04 |
Benzyl Benzoate Application BP 25% |
Scabies - not first choice |
05.01.01.01 |
Benzylpenicillin |
|
11.03.01 |
Benzylpenicillin |
Unlicensed special - Ophthalmology Only |
04.06 |
Betahistine Dihydrochloride |
Meniere's disease |
06.03.02 |
Betamethasone Betnesol® |
|
06.03.02 |
Betamethasone |
|
13.04 |
Betamethasone 0.025% Betnovate-RD® |
|
13.04 |
Betamethasone 0.05% with Salicylic Acid 3% Diprosalic® |
|
13.04 |
Betamethasone 0.1% Betnovate® |
|
13.04 |
Betamethasone 0.1% with Fucidic Acid 2% Fucibet® |
|
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% ear drops Betnesol N® |
|
11.04.01 |
Betamethasone 0.1% with Neomycin 0.5% eye drops Betnesol N® |
|
12.02.03 |
Betamethasone 0.1% with neomycin 0.5% nasal drops |
|
12.01.01 |
Betamethasone ear drops |
|
11.04.01 |
Betamethasone eye drops |
|
11.04.01 |
Betamethasone eye ointment Betnesol® |
|
12.02.01 |
Betamethasone nasal drops |
|
13.04 |
Betamethasone valerate medicated plaster Betesil® |
|
11.06 |
Betaxolol Betoptic® |
|
08.01.05 |
Bevacizumab Avastin® |
Only on formulary for use in treating advanced or unresectable hepatocellular carcinoma with atezolizumab as per NICE TA 666 |
20 |
Bevacizumab intravitreal injection |
Only for neovascular eye conditions not covered by NICE recommendations. |
02.12 |
Bezafibrate |
Prescribe generically |
06.01.06 |
BG Star® |
Category 2 |
19.12 |
Biatain Silicone adhesive 10cm x 10cm |
A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border. |
19.12 |
Biatain Silicone adhesive 12.5cm x 12.5cm |
A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border. |
19.12 |
Biatain Silicone adhesive 15cm x 15cm |
A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border. |
19.12 |
Biatain Silicone adhesive 7.5cm x 7.5cm |
A soft, absorbent polyurethane foam pad with a vapour-permeable film backing and a silicone adhesive border. |
08.03.04.02 |
Bicalutamide |
|
05.03.01 |
Bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg Biktarvy |
HIV infection only
NHSE clinical commissioning policy 170131P |
11.06 |
Bimatoprost Lumigan® |
Second line after latanoprost.
0.1mg per ml (100mcg per ml) available in 3ml bottles
0.3mg per ml (300mcg per ml) available in single dose containers only
|
11.06 |
Bimatoprost with Timolol Ganfort® |
|
08.01.05 |
Binimetinib Mektovi ® |
|
12.03.05 |
Biotene Oralbalance® gel |
ACBS |
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
Mix 25 and Mix 50 |
06.01.01.02 |
Biphasic Isophane Insulin Hypurin® Porcine 30/70 Mix |
|
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
|
06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb |
Comb 15 - 3ml cartridges
Comb 25 - 5ml vials, 3ml cartridges & Solostar pen
Comb 50 - 3ml cartridges |
12.02.03 |
BIPP Gauze |
|
01.06.02 |
Bisacodyl |
Includes tablets and suppositories
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
01.03.03 |
Bismuth subsalicylate Pepto-Bismol® |
Only for use in accordance with SCAN guideline |
02.04 |
Bisoprolol |
|
09.05.01.02 |
Bisphosphonates |
See Chapter 6.6 or individual drugs : disodium pamidronate, zoledronic acid |
02.08.01 |
Bivalirudin Angiox® |
|
08.01.02 |
Bleomycin |
|
08.02.03 |
Blinatumomab Blincyto® |
|
14.04 |
Boostrix-IPV |
Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
For pregnant women at risk of whooping cough |
07.02.02 |
Boric acid |
For use by Solent Sexual Health Only |
08.01.05 |
Bortezomib Velcade® |
|
08.01.05 |
Bosutinib Bosulif® |
|
01.07.04 |
Botulinum toxin type A |
Anal fissure - approved off-licence indication |
04.07.04.02 |
Botulinum Toxin Type A Botox® |
Migraine prophylaxis |
04.09.03 |
Botulinum Toxin Type A |
Refer to list of approved indications |
14.04 |
Botulism antitoxin |
Specialist clinics only |
08.01.05 |
Brentuximab vedotin Adcetris® |
|
08.01.05 |
Brigatinib Alunbrig® |
|
13.06 |
Brimonidine gel Mirvaso® |
|
11.06 |
Brimonidine Tartrate generic |
|
11.06 |
Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® |
|
11.06 |
Brinzolamide generic |
May be better tolerated than dorzolamide |
11.06 |
Brinzolamide 1% with Timolol 0.5% Azarga® |
|
11.06 |
Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza® |
|
04.08.01 |
Brivaracetam Briviact® |
Consultant neurologist only to initiate for patients with refractory epilepsy and where other antiepileptics are contraindicated, ineffective or not tolerated.
Specialist to establish benefit and stabilise dose before request is made to GP to provide ongoing prescriptions.
|
13.05.03 |
Brodalumab Kyntheum® |
|
11.08.02 |
Bromfenac Yellox® |
|
04.09.01 |
Bromocriptine |
|
06.07.01 |
Bromocriptine |
Secondary Care initiated |
01.05.02 |
Budesonide Entocort® |
Full course to be supplied by the hospital. |
03.02 |
Budesonide |
MDI / Turbohaler / nebuliser solution |
01.05.02 |
Budesonide 2mg/dose rectal foam Budenofalk® |
Second line option whilst Colifoam not available |
01.05.02 |
Budesonide 3mg capsules Budenofalk® |
When used for relapses of small bowel Crohn's disease - full course to be supplied by hospital.
Amber Initiated when prescribed for autoimmune hepatitis - course may be continued in primary care. |
03.02 |
Budesonide and formoterol Symbicort® |
|
03.02 |
Budesonide and formoterol DuoResp Spiromax® |
Alternative to Symbicort for new initiations. Adults only (over 18). Prescribe by brand name |
01.05.02 |
Budesonide m/r tablets Cortiment MMX® |
To induce remission in mild to moderate active ulcerative colitis - full course to be supplied by hospital |
02.02.02 |
Bumetanide |
|
15.02 |
Bupivacaine and adrenaline |
Bupivacaine 0.25% with adrenaline 1 in 200,000
Bupivacaine 0.5% with adrenaline 1 in 200,000 |
15.02 |
Bupivacaine hydrochloride |
Bupicvacaine 0.25% and 0.5% |
15.02 |
Bupivacaine with fentanyl |
Bupivacaine 0.1% with fentanyl 2 micrograms per ml |
04.07.02 |
Buprenorphine |
Moderate to severe pain |
04.10.03 |
Buprenorphine |
Opioid dependence
Awaiting shared care guideline |
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
Substance Misuse services only |
04.07.02 |
Buprenorphine transdermal patch BuTrans®, Butec® |
Moderate non-cancer pain requiring an opioid analgesic if other agents by the oral route are not suitable or not tolerated.
Change patch every 7 days.
Prescribe by brand name. In primary care the most cost effective brand is Butec |
04.07.02 |
Buprenorphine transdermal patch Transtec® Bupeaze® |
Moderate to severe chronic pain including cancer pain requiring an opioid analgesic where oral morphine is unsuitable or not tolerated. Palliative care.
Change patch every 4 days.
Prescribe by brand name. In primary care the cost effective brand is Bupeaze |
04.10.02 |
Bupropion Hydrochloride Zyban® |
As part of smoking cessation programme |
04.01.02 |
Buspirone Hydrochloride |
For use by Southern Health as per the anxiety treatment guidelines only |
08.01.01 |
Busulfan |
|
03.04.03 |
C1 Esterase Inhibitor Berinert® Cinryze® |
Acute Treatment or Short-term prophylaxis prior to planned procedures for Hereditary Angioedema and Acquired Angioedema in accordance with NHS England commissioning policy.
Prophylactic treatment of hereditary angioedema (HAE) types I and II in accordance with NHS England commissioning policy - specialist centres only (UHS)
|
08.01.05 |
Cabazitaxel Jevtana® |
|
04.09.01 |
Cabergoline |
|
06.07.01 |
Cabergoline |
|
08.01.05 |
Cabozantinib Cabometyx® |
|
08.01.05 |
Cabozantinib Cometriq® |
For treating medullary thyroid cancer |
03.05.01 |
Caffeine citrate solution 20mg/ml Peyona® |
Neonatal unit only. Peyona can be used for intravenous infusion and oral administration. |
13.03 |
Calamine |
|
09.06.04 |
Calceos® |
Calcium carbonate 1.25 g (calcium 500 mg), colecalciferol 10 micrograms (400 units) per tablet |
09.05.01.01 |
Calcichew® |
Calcium carbonate 1.25 g (calcium 500 mg or Ca2+ 12.5 mmol) per tablet |
09.06.04 |
Calcichew-D3® Forte |
Calcium carbonate 1.25 g (calcium 500 mg) colecalciferol 10 micrograms (400 units) per tablet |
13.05.02 |
Calcipotriol Dovonex® |
|
13.05.02 |
Calcipotriol with betamethasone Dovobet® |
Gel can be used on the scalp and body |
13.05.02 |
Calcipotriol with betamethasone Enstilar® |
|
06.06.01 |
Calcitonin (salmon) / Salcatonin |
Secondary Care only |
09.06.04 |
Calcitriol |
|
13.05.02 |
Calcitriol ointment Silkis® |
For flexures and vulval psoriasis |
18 |
Calcium chloride injection |
|
09.05.02.02 |
Calcium Acetate Phosex® |
|
09.06.04 |
Calcium and Ergocalciferol |
|
09.05.02.02 |
Calcium Carbonate Calcichew® |
|
09.05.01.01 |
Calcium Chloride |
|
08.01 |
Calcium Folinate |
Folinic acid rescue. Adjunct to 5-fluorouracil. |
18 |
Calcium folinate injection |
Methotrexate overdose |
09.05.01.01 |
Calcium Gluconate |
|
18 |
Calcium gluconate gel |
|
18 |
Calcium gluconate injection |
|
08.01 |
Calcium Levofolinate |
Adjunct to 5-fluorouracil in colorectal cancer |
09.05.02.02 |
Calcium Salts Osvaren® |
Red for renal dialysis patients |
09.05.01.01 |
Calcium syrup Alliance |
Paediatrics only on specialist advice. Contains calcium 2.55mmol in 5ml.
Alliance Calcium Syrup is a food supplement but it can be prescribed on FP10. |
13.02.01 |
Calmurid® cream |
Contains 10% urea |
13.07 |
Camellia sensis Catephen® |
For use by Solent Sexual Health Only |
06.01.02.03 |
Canagliflozin Invokana▼® |
|
02.05.05.02 |
Candesartan |
|
02.09 |
Cangrelor |
Information on restriction - Only for patients undergoing primary PCI where oral administration of P2Y12 inhibitor is not possible.
|
04.08.01 |
Cannabidiol Epidyolex |
|
10.02.02 |
Cannabis extract Sativex® |
Hospital only agent until a shared care guideline is approved
Approved only for use as per NICE criteria |
13.09 |
Capasal® |
Coal tar 1%, coconut oil 1%, salicyclic acid 0.5% |
08.01.03 |
Capecitabine |
|
12.03.01 |
Caphosol® |
Prophylaxis and treatment of oral mucositis in patients with head and neck cancer receiving radiotherapy with or without chemotherapy |
09.01 |
Caplacizumab Cablivi® |
|
10.03.02 |
Capsaicin 0.025% cream Zacin |
Adjunct for knee and hand OA |
10.03.02 |
Capsaicin 0.075% cream Axsain |
Option for localised neuropathic pain including diabetic neuropathy |
04.07.03 |
Capsaicin cream Axsain® |
|
02.05.05.01 |
Captopril |
Paediatrics only |
04.07.03 |
Carbamazepine Tegretol |
Trigeminal neuralgia |
04.08.01 |
Carbamazepine |
Includes tablets, MR tablets, liquid and suppositories. (Chewtabs discontinued)
Suppositories are HIGH COST in primary care (£120.00 for 5)
MHRA/CHM Advice on switching:
Category 1: ensure patient is maintained on a specific manufacturer's product. |
06.02.02 |
Carbimazole |
|
03.07 |
Carbocisteine |
Capsules 375mg and syrup 250mg in 5ml
Oral solution 750mg in 10ml sachets are a cost-effective option if liquid is required. |
11.08.01 |
Carbomer 980 gel (eye drops) Clinitas®, Viscotears® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
08.01.05 |
Carboplatin |
|
07.01.01 |
Carboprost Hemabate® |
|
06.01.01.03 |
CareFine |
|
08.01.05 |
Carfilzomib Kyprolis® |
|
11.08.01 |
Carmellose sodium 0.5% eye drops Optive Fusion®, Optive Plus® |
Optive Plus contains castor oil in addition to carmellose and glycerol
Optive Fusion contains hyaluronic acid in addition to carmellose and glycerol
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
11.08.01 |
Carmellose unit dose eye drops Celluvisc® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
08.01.01 |
Carmustine Gliadel® |
|
A2.05.02 |
Carobel, Instant® |
OTC product to thicken baby milk for reflux |
02.04 |
Carvedilol |
Second line agent for heart failure after bisoprolol |
05.02.04 |
Caspofungin |
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
07.04.04 |
Catheter Patency Solutions |
|
05.01.02.01 |
Cefaclor |
|
05.01.02.01 |
Cefalexin |
|
05.01.02.01 |
Cefixime Suprax® |
GUM only |
05.01.02.01 |
Cefotaxime |
|
05.01.02.01 |
Ceftazidime |
|
11.03.01 |
Ceftazidime |
Unlicensed special - Ophthalmology only |
05.01.02.01 |
Ceftazidime/azibactam Zavicefta® |
On microbiologist advice only |
05.01.02 |
Ceftolozane 1g tazobactam 0.5g Zerbaxa® |
Resistant pseudomonal infections - microbiologist recommendation only |
05.01.02.01 |
Ceftriaxone |
|
05.01.02.01 |
Cefuroxime |
|
11.03.01 |
Cefuroxime |
Unlicensed special - Ophthalmology only
|
11.03.01 |
Cefuroxime Aprokam® |
Prophylaxis of endophthalmitis after cataract surgery |
10.01.01 |
Celecoxib |
Not to be used in patients with cardiovascular disease |
08.01.05 |
Cemiplimab Libtayo® |
|
08.01.05 |
Ceritinib Zykadia |
|
10.01.03 |
Certolizumab Pegol |
|
03.04.01 |
Cetirizine |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
13.02.01 |
Cetraben® |
Cream, Ointment, Lotion |
08.01.05 |
Cetuximab Erbitux® |
|
04.01.01 |
Chloral Betaine |
For use in pregnancy.
Note HIGH COST in primary care. |
04.01.01 |
Chloral Hydrate |
Note HIGH COST in primary care |
08.01.01 |
Chlorambucil |
|
05.01.07 |
Chloramphenicol Kemicetine® |
|
11.03.01 |
Chloramphenicol |
NHS England low value medicine
A prescription for treatment of conjunctivitis should not be routinely offered in primary care as the condition is sel-limiting and will clear up on its own without the need for treatment
|
04.01.02 |
Chlordiazepoxide |
Alcohol withdrawal |
13.11.02 |
Chlorhexidine 0.015% with cetrimide 0.15% Travasept® |
|
13.11.02 |
Chlorhexidine 0.015% with Cetrimide 0.15% Tisept® |
|
13.11.02 |
Chlorhexidine 0.05% |
|
12.02.03 |
Chlorhexidine 0.1%, neomycin 0.5% cream Naseptin® |
|
13.11.02 |
Chlorhexidine 0.5% |
|
13.11.02 |
Chlorhexidine 2% in Isopropyl Alcohol 70% ChloraPrep® |
|
13.11.02 |
Chlorhexidine 4% Hibiscrub® |
|
11.03.01 |
Chlorhexidine digluconate 0.2% eye drops |
Unlicensed |
12.03.04 |
Chlorhexidine gluconate |
|
05.04.01 |
Chloroquine |
Travel Prophylaxis - Private Prescription |
02.02.01 |
Chlorothiazide 250mg in 5ml |
Paediatrics only |
03.04.01 |
Chlorphenamine |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
04.02.01 |
Chlorpromazine |
|
04.06 |
Chlorpromazine |
|
14.04 |
Cholera vaccine Dukoral® |
For adults travelling to at risk areas |
12.03.01 |
Choline Salicylate Bonjela® Adult |
|
03.02 |
Ciclesonide Alvesco® |
|
08.02.02 |
Ciclosporin |
Prescribe by brand |
08.02.02 |
Ciclosporin Sandimmun® |
|
13.05.03 |
Ciclosporin Vanquoral® |
|
11.99.99.99 |
Ciclosporin A 0.1% Verkazia |
For severe keratoconjuctivitis in children from four years of age and adolescents |
11.99.99.99 |
Ciclosporin eye drops Ikervis® |
|
01.03.01 |
Cimetidine |
Includes tablets and oral solution
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
09.05.01.02 |
Cinacalcet Mimpara® |
NICE TA 117 Secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.
NHS England commission cinacalcet for complex primary hyperparathyroidism in accordance with policy 16034/P.
|
04.06 |
Cinnarizine |
NHS England low value medication
A prescription for the treatment of travel sickness should not routinely be offered in primary care as the condition is appropriate for self-care. |
05.01.12 |
Ciprofloxacin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
11.03.01 |
Ciprofloxacin |
|
15.01.05 |
Cisatracurium Nimbex® |
Only for patients who are allergic to other agents and when vecuronium is not available. |
08.01.05 |
Cisplatin |
|
04.03.03 |
Citalopram |
Maximum dose 40mg/ day, 20mg in elderly or liver dysfunction. Refer to MHRA and local advice concerning QQT prolongation |
08.01.03 |
Cladribine |
|
08.01.03 |
Cladribine Mavenclad® |
Approved in accordance with NICE TA493 for treating relapsing–remitting multiple sclerosis. |
05.01.05 |
Clarithromycin |
Intravenous infusion |
05.01.05 |
Clarithromycin |
|
05.01.06 |
Clindamycin |
Restricted indications - refer to PHT Microguide antimicrobial guidelines |
05.01.06 |
Clindamycin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
05.01.06 |
Clindamycin |
Unlicensed special listed in Drug Tariff Paediatrics only |
07.02.02 |
Clindamycin Dalacin® |
|
13.06.01 |
Clindamycin 1% Dalacin T® |
|
13.06.01 |
Clindamycin/ tretinoin gel Treclin® |
|
19.23 |
Clinifast Red, Green, Blue, Yellow and beige lines |
Available in 1m, 3m and 5m lengths. |
19.20 |
Clinipod 20ml x 25 pods sodium chloride 0.9% |
Normal saline is the irrigation solution of choice. all irrigation solutions should be applied at body temperature. tap water is only to be used according to local policy for leg washing and all chronic and acute wounds will be cleansed with a setile, single use solution, if required. |
19.21 |
Clinipore tape 2.5cm x 5m |
|
19.21 |
Clinipore tape 5cm x 5m |
|
19.14 |
Clinisorb 10cm x 10cm |
Sterile activated charcoal cloth. Apply as a secondary dressing over an appropriate primary dressing. Exudate will reduce the dressings effectiveness. Can be cut to size. Can be used in the management of malodourous wounds such as fungating wounds, pressure ulcers, leg ulcers and diabetic foot ulcers. |
19.14 |
Clinisorb 10cm x 20cm |
Sterile activated charcoal cloth. Apply as a secondary dressing over an appropriate primary dressing. Exudate will reduce the dressings effectiveness. Can be cut to size. Can be used in the management of malodourous wounds such as fungating wounds, pressure ulcers, leg ulcers and diabetic foot ulcers. |
19.14 |
Clinisorb 15cm x 25cm |
Sterile activated charcoal cloth. Apply as a secondary dressing over an appropriate primary dressing. Exudate will reduce the dressings effectiveness. Can be cut to size. Can be used in the management of malodourous wounds such as fungating wounds, pressure ulcers, leg ulcers and diabetic foot ulcers. |
04.08.01 |
Clobazam |
Epilepsy only - SLS
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
|
13.04 |
Clobetasol propionate 0.05% shampoo Etrivex® |
|
13.04 |
Clobetasone Butyrate 0.05% Eumovate® |
|
05.01.10 |
Clofazimine |
|
04.01.01 |
Clomethiazole |
|
06.05.01 |
Clomifene Citrate |
Secondary Care initiated
Fertility treatment |
04.03.01 |
Clomipramine |
Psychiatry only: refer to anxiety treatment guidelines |
04.08.01 |
Clonazepam |
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
04.08.02 |
Clonazepam Injection |
|
02.05.02 |
Clonidine Catapres® |
|
04.07.04.02 |
Clonidine |
|
20 |
Clonidine oral solution |
Premedication/sedation of children prior to surgery |
02.09 |
Clopidogrel |
Prescribe generically |
02.09 |
Clopidogrel 1mg in 1ml |
Unlicensed special listed in Drug Tariff
Paediatrics only |
07.02.02 |
Clotrimazole |
10% vaginal cream
200mg pessaries
500mg pessary |
12.01.01 |
Clotrimazole 1% Canesten® |
|
13.10.02 |
Clotrimazole 1% |
NHSE low value medication
A prescription for the treatment of ringworm or athlets foot should not routinely be offered in primary care as the condition is appropriate for self-care |
04.02.01 |
Clozapine |
Specialist use only. Special requirements for monitoring. |
13.05.02 |
Coal tar lotion 5% Exorex® |
|
13.05.02 |
Coal tar ointment |
Coal tar 2%, 5%, 10% w/w in an ointment base
Unlicensed special on BAD list and in Drug Tariff |
13.05.02 |
Coal tar paste BP |
|
13.05.02 |
Coal tar scalp pomade |
Unlicensed special on BAD list and in Drug Tariff
Coal tar solution BP 6% w/w and salicyclic acid 2% w/w in emulsifying ointment |
13.05.02 |
Coal tar solution BP 3.3% w/w and propylene glycol 20% in Synalar gel |
Included on BAD specials list 2014 |
13.05.02 |
Coal tar solution BP 5% in betamethasone valerate 0.025% ointment |
Unlicensed special on BAD list and in Drug Tariff. |
13.05.02 |
Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. Merck |
|
02.02.04 |
Co-amilofruse (amiloride/furosemide) |
2.5mg/20mg and 5mg/40mg tablets |
02.02.04 |
Co-amilozide (amiloride/hydrochlorothiazide) |
2.5mg/25mg and 5mg/50mg tablets |
05.01.01.03 |
Co-Amoxiclav |
Restricted indications - please refer to Microguide or NICE prescribing guidance |
19.23 |
Coban 2 Comfort foam layer (layer 1) 10cm x 3.5m |
|
19.23 |
Coban 2 Comfort foam layer (layer 1) 15cm x 3.5m |
15cm width bandage should be used for applying to the knee and thigh of patients with chronic oedema. |
19.23 |
Coban 2 Compression layer (layer 2) 10cm x 4.5m |
|
19.23 |
Coban 2 Compression layer (layer 2) 15cm x 4.5m |
The Coban 2 15cm width bandage should be used for applying reduced compression to the knee and thigh of patients with chronic oedema. |
19.23 |
Coban 2 Layer compression system Kit |
Multi-layer compression bandage kit. Bandages of choice for lymphoedema/coedema management.
Coban 2 system is second-line for patients requiring full compression where Actico is considered inappropriate, known latex allergies or slippage may be a concern. |
19.23 |
Coban 2 Lite Comfort foam layer (layer 1) 10cm x 2.7m |
|
19.23 |
Coban 2 Lite Comfort foam layer (layer 1) 15cm x 2.7m |
The Coban 2 lite comfort 15cm width bandage should be used for applying reduced compression to the knee and thigh of patients with chronic oedema. |
19.23 |
Coban 2 Lite Compression layer (layer 2) 10cm x 3.5m |
|
19.23 |
Coban 2 Lite Compression layer (layer 2) 15cm x 3.5m |
15cm width bandage should be used for applying reduced compression to the knee and thigh of patients with chronic oedema. |
19.23 |
Coban 2 Lite compression system Kit |
Designed to be more comfitable to patients less tolerant of compression therapy and/or who require reduced compression thepray.
This system is designed to be used as a kit and should not be used with other wadding or bandages.
|
04.09.01 |
Co-Beneldopa Madopar® |
|
15.02 |
Cocaine |
Cocaine paste 25%
Cocaine solution 5%
Anaesthetics, A&E , ENT only |
11.07 |
Cocaine 4% eye drops |
|
04.09.01 |
Co-Careldopa Sinemet® |
|
04.09.01 |
Co-Careldopa Duodopa® |
Specialist use in line with NHSE Commissioning Policy D04/P/e |
13.06.02 |
Co-Cyprindiol |
Dermatology only – for women who also wish to receive oral contraception |
01.06.02 |
Co-danthramer |
Includes capsules and suspension. Only for treatment of terminally ill patients. |
03.09.01 |
Codeine Linctus BP |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
04.07.02 |
Codeine Phosphate injection |
|
01.04.02 |
Codeine phosphate tablets |
|
04.07.02 |
Codeine phosphate tablets |
Moderate to severe pain |
10.01.04 |
Colchicine tablets |
|
09.06.04 |
Colecalciferol 20,000 units Fultium-D3® |
|
09.06.04 |
Colecalciferol 25,000 unit oral solution Invita D3® |
|
09.06.04 |
Colecalciferol 3200 unit capsules Fultium-D3® |
|
09.06.04 |
Colecalciferol 50,000 unit oral solution Invita D3® |
|
09.06.04 |
Colecalciferol 800 units Fultium-D3®, Invita D3® |
|
09.06.04 |
Colecalciferol 800 units Desunin® |
For patients who prefer a tablet formulation |
02.12 |
Colesevelam Cholestagel® |
Symptomatic bile salt salt malabsorption with severe diarrhoea - second line after cholestyramine. Consultant gastroenterologist only. |
01.09.02 |
Colestyramine Questran® |
|
02.12 |
Colestyramine |
|
02.12 |
Colestyramine Questran® |
Contains sucrose |
02.12 |
Colestyramine Questran® Light |
Sugar-free |
05.01.07 |
Colistimethate sodium for injection or nebulisation Colomycin® |
via nebuliser for non-CF bronchiectasis - refer to shared care agreement |
05.01.07 |
Colistimethate sodium for injection or nebulisation Colomycin® Promixin® |
Cystic fibrosis in accordance with NHSE policy A01/P/b |
05.01.07 |
Colistimethate sodium inhaler Colobreathe® |
|
13.10.05 |
Collodion Flexible BP |
|
01.01.01 |
Co-magaldrox Maalox® |
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
06.04.01.01 |
Combined continuous HRT patch Evorel® Conti |
|
06.04.01.01 |
Combined continuous HRT tablet Kliofem, Kliovance, Femoston Conti |
|
06.04.01.01 |
Combined cyclical HRT patch Evorel® Sequi |
Patches only are formulary |
06.04.01.01 |
Combined cyclical HRT tablet Elleste-Duet®, Femoston |
Elleste Duet first choice for cost
Femoston 1/10 or 2/10
|
07.03.01 |
Combined Hormonal Contraceptives Qlaira® |
Only on specialist initiation where:
- contraception and relief of peri-menopausal symptoms is required
- As a fourth line option for women with heavy menstrual bleeding
|
07.03.01 |
Combined Hormonal Contraceptives SyreniRing® |
Secondary care initiated
SyreniRing replaces NuvaRing as the preferred option for women requiring vaginal ring contraceptive |
07.03.01 |
Combined Hormonal Contraceptives Evra |
For women with proven lactose allergy or malabsorption problems who cannot take the combined pill. |
07.03.01 |
Combined Hormonal Contraceptives Logynon ED® |
|
07.03.01 |
Combined Hormonal Contraceptives Microgynon 30 ED® |
|
07.03.01 |
Combined Hormonal Contraceptives Loestrin 30® |
|
07.03.01 |
Combined Hormonal Contraceptives Femodene® ED |
|
19.06 |
Comfeel Plus Ulcer 10cm x 10cm |
Absorbant hydrocolldoid dressing with added alginate for absorption, a vapour-permeable film backing and bevelled edge. |
19.06 |
Comfeel Plus Ulcer 15cm x 15cm |
Absorbant hydrocolldoid dressing with added alginate for absorption, a vapour-permeable film backing and bevelled edge. |
19.06 |
Comfeel Plus Ulcer 4cm x 6cm |
Absorbant hydrocolldoid dressing with added alginate for absorption, a vapour-permeable film backing and bevelled edge. |
19.23 |
Comfifast |
Available in 1m, 3m and 5m lengths. |
09.02.02.01 |
Compound sodium lactate intravenous infusion |
|
19.23 |
Comprilan 10cm x 5m |
Reusable system (washable) High cotton content. For specialist chronic oedema management. |
06.01.06 |
Contour TS® |
Category 1 acceptable |
05.01.08 |
Co-trimoxazole |
Restricted use - refer to BNF |
05.01.08 |
Co-trimoxazole |
Restricted use - refer to BNF and microguide |
05.04.08 |
Co-trimoxazole |
|
06.01.06 |
Coutour Next® |
Category 2 |
08.01.05 |
Crisantaspase Erwinase® |
|
08.01.05 |
Crizotinib Xalkori® |
|
13.03 |
Crotamiton Eurax® |
|
19.15 |
Cutimed Sorbact Swab 4cm x 6cm |
DACC-coated, hydrophobic, antimicrobial wound contact layer. Primary dressing for contaminated, colonised or infected superficial or deep wounds including superficial wounds. traumatic, post-operative or dehisced wounds, ulcers and fungal infections in the groin, skin folds or between digits. |
19.15 |
Cutimed Sorbact Swab 7cm x 9cm |
DACC-coated, hydrophobic, antimicrobial wound contact layer. Primary dressing for contaminated, colonised or infected superficial or deep wounds including superficial wounds. traumatic, post-operative or dehisced wounds, ulcers and fungal infections in the groin, skin folds or between digits. |
04.06 |
Cyclizine |
|
13.10.04 |
Cyclomethicone 50% / Isopropyl myristate 50% solution Full Marks solution |
Physical (non-chemical) insecticide for managment of head lice.
NHS England low value medication
A prescription for the treatment of head lice should not routinely be offered in primary care as the condition is suitable for self-care |
11.05 |
Cyclopentolate eye drops and unit dose eye drops |
0.5 % and 1% drops and preservative-free unit dose drops (Minims) |
08.01.01 |
Cyclophosphamide |
Injection, tablets |
03.04.01 |
Cyproheptadine Periactin® |
For SSRI overdose |
18 |
Cyproheptadine tablets Periactin® |
Serotonin syndrome |
08.03.04.02 |
Cyproterone |
Secondary Care initiated |
06.04.02 |
Cyproterone Acetate |
|
08.01.03 |
Cytarabine |
|
02.08.02 |
Dabigatran Pradaxa® |
VTE Prophylaxis following elective hip and knee replacement (full course to be supplied by hospital).
Stroke prevention in non-valular AF
DVT and PE treatment and secondary prevention |
08.01.05 |
Dabrafenib Tafinlar® |
|
08.01.05 |
Dacarbazine |
|
08.01.05 |
Dacomitinib monohydrate Vizimpro® |
|
08.01.02 |
Dactinomycin Cosmegen Lyovac® |
|
05.01.07 |
Dalbavancin Xydalba® |
On microbiologist advice only |
02.08.01 |
Danaparoid Orgaran® |
|
06.07.02 |
Danazol |
Product discontinued and only available as an imported product.
For prescribing by specialists for long-term prophylaxis of hereditary angioedema only. |
10.02.02 |
Dantrolene capsules |
|
18 |
Dantrolene injection |
Neuroleptic malignant syndrome |
15.01.08 |
Dantrolene Sodium Dantrium Intravenous® |
|
06.01.02.03 |
Dapagliflozin Forxiga▼® |
For use in type 2 diabetics
For use in type 1 diabetics
|
05.01.10 |
Dapsone |
Dermatitis herpetiformis - dermatology only |
05.01.07 |
Daptomycin Cubicin® |
Consultant microbiologist only |
08.01.05 |
Daratumumab Darzalex® |
|
09.01.03 |
Darbepoetin Alfa Aranesp® |
|
07.04.02 |
Darifenacin Emselex® |
|
08.03.04.02 |
Darolutamide Nubeqa® |
|
05.03.01 |
Darunavir Prezista® |
HIV infection only |
05.03.01 |
Darunavir and Cobicistat Rezolsta® |
HIV infection only |
05.03.03.02 |
Dasabuvir Exviera® |
|
08.01.05 |
Dasatinib Sprycel® |
|
08.01.02 |
Daunorubicin |
|
09.01.03 |
Deferasirox Exjade® |
Commissioned by NHS England for iron chelation in thalassaemia, sickle cell and rare inherited anaemias (Policy 16070/P) |
09.01.03 |
Deferiprone Ferriprox® |
Commisioned by NHS England for iron chelation in thalassaemia, sickle cell and rare inherited anaemias (Policy 16070/P) |
08.03.04.02 |
Degarelix Firmagon® |
|
09.06.07 |
DEKAs/DEKAs Plus |
Vitamin and mineral supplements for use when recommended by a specialist in patients with cystic fibrosis |
05.01.03 |
Demeclocycline |
SIADH treatment only
Note HIGH COST in primary care |
06.06.02 |
Denosumab Prolia® |
May be initiated in primary care or first injection in secondary care
Prescribe by brand name (Prolia) |
06.06.02 |
Denosumab XGEVA® |
Secondary Care initiated
Prescribe by brand name (XGEVA) |
13.11 |
Dequalinium chloride Fluomizin® |
For use by Solent Sexual Health Service only |
13.08.02 |
Dermacolor® |
Dermatology only. Other brands (Covermark, Keromask, Veil) may be prescribed on specialist advice - all ACBS.) |
13.02.01 |
Dermamist® spray |
White soft paraffin 10% in liquid paraffin and coconut oil |
13.02.01 |
Dermatonics® Heel Balm® |
Contains 25% urea |
13.09 |
Dermax® shampoo benzalkonium chloride 0.5% |
|
13.02.01 |
Dermol® |
500 Lotion and Cream |
18 |
Desferrioxamine injection |
|
09.01.03 |
Desferrioxamine Mesilate |
Commissioned by NHS England for iron chelation in thalassaemia, sickle cell and rare inherited anaemias (Policy 16070/P) |
15.01.02 |
Desflurane |
|
03.04.01 |
Desloratadine |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
06.05.02 |
Desmopressin |
Sublingual tablets are second line |
07.03.02.01 |
Desogestrel 75mcg tablets Cerelle® |
Use generic in primary care or Cerelle in peanut/soya allergy |
06.03.02 |
Dexamethasone |
|
12.01.01 |
Dexamethasone and ciprofloxacin Cilodex® |
|
11.04.01 |
Dexamethasone eye drops Maxidex® |
|
11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
|
11.04.01 |
Dexamethasone preservative free unit dose |
|
12.01.01 |
Dexamethasone with neomycin Otomize® |
|
11.04.01 |
Dexamethasone with neomycin and polymyxin B sulphate Maxitrol® |
|
12.01.01 |
Dexamethasone,framycetin and gramicidin Sofradex® |
|
04.04 |
Dexamfetamine |
Children - CAMHS initiation only
CAMHS Shared care agreement for Hampshire will be available on iDOCs
Adults - diagnosis and treatment initiation via Hampshire ADHD service (provided by Surrey and Borders Partnership NHSFT)
Awaiting shared care guidelines |
08.01 |
Dexrazoxane Savene® |
For the treatment of anthracycline extravasation in accordance with PHT guidelines.
Contact oncology pharmacist. |
09.02.02.02 |
Dextran 70® |
|
04.07.02 |
Diamorphine Injection |
Severe pain |
04.07.02 |
Diamorphine nasal spray Ayendi® |
For paediatric emergency use only
Refer to Drug Therapy Guideline |
04.01.02 |
Diazepam |
Short term use only |
04.08.02 |
Diazepam Injection |
|
04.08.02 |
Diazepam Rectal Tubes |
|
10.02.02 |
Diazepam tablets |
|
02.05.01 |
Diazoxide 250mg in 5ml |
Unlicensed special listed in Drug Tariff
Paediatrics only |
20 |
Dibotermin Alfa, rhBMP-2 InductOs® |
Contact directorate pharmacist for advice/orders
NHS England are responsible for commissioning use in complex spinal surgery at specialist centres (Policy 16063/P) |
10.01.01 |
Diclofenac |
EC tablets, SR capsules, suppositories, injection
Dispersible tablets only if necessary |
13.08.01 |
Diclofenac Solaraze® |
|
15.01.04.02 |
Diclofenac |
IM injection only in primary care. |
10.03.02 |
Diclofenac Gel 1% |
Knee and hand OA
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
10.01.01 |
Diclofenac with Misoprostol Arthrotec 50 and 75® |
Only for patients with high risk of GI bleed |
18 |
Dicobalt edetate injection |
Cyanide poisoning |
01.02 |
Dicycloverine tablets |
High cost in primary care |
05.03.01 |
Didanosine Videx® |
HIV infection only |
08.03.01 |
Diethylstilbestrol |
|
13.04 |
Diflucortolone Valerate 0.1% Nerisone® |
|
13.04 |
Diflucortolone Valerate 0.3% Nerisone Forte® |
|
02.01.01 |
Digoxin |
|
02.01.01 |
Digoxin |
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
For cardiac glycoside (digoxin) toxicity |
18 |
Digoxin specific antibody fragments Digifab® |
Digoxin overdose |
04.07.02 |
Dihydrocodeine |
Non MR tablets only |
04.07.02 |
Dihydrocodeine MR |
|
02.06.02 |
Diltiazem |
60mg tablets - prescribe generically |
01.07.04 |
Diltiazem 2% Cream Anoheal® |
Only for chronic anal fissures unresponsive to GTN.
Unlicensed in the UK. |
02.06.02 |
Diltiazem Hydrochloride |
Dilzem SR, Adizem SR, Tildiem Retard (twice daily dosage).
Different versions of modified-release preparations containing more than 60mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed. |
02.06.02 |
Diltiazem Hydrochloride |
Adizem XL, Dilzem XL, Viazem XL, Zemtard XL Tildiem LA (once daily dosage).
Different versions of modified-release preparations containing more than 60mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed. |
18 |
Dimercaprol injection |
|
13.05.03 |
Dimethyl fumarate Skilarence® |
|
07.01.01 |
Dinoprostone Prostin E2® |
|
08.01.05 |
Dinutuximab beta Qarziba® |
NICE TA 538: Dinutuximab beta for treating neuroblastoma |
13.10.03 |
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v |
For use in dermatology only.
Diphenylcyclopropenone (DCP) is a highly sensitising agent used to treat alopecia areata and resistant viral warts as topical immunotherapy. It should be applied only in Dermatology departments by a trained professional.
Unlicensed special on BAD list
|
13.02.01 |
Diprobase® |
Zerobase is a lower cost alternative for primary care prescribing |
02.09 |
Dipyridamole MR capsules Persantin® Retard |
|
11.99.99.99 |
Disodium edetate 0.37% |
|
06.06.02 |
Disodium Pamidronate |
Secondary Care only |
02.03.02 |
Disopyramide |
|
07.04.01 |
Distigmine Bromide Ubretid® |
Urology only |
04.10.01 |
Disulfiram Antabuse® |
Substance Misuse Service only |
13.05.02 |
Dithranol Dithrocream® |
|
13.05.02 |
Dithranol in Lassar's Paste |
Strengths 0.1%. 0.5%, 1%, 2%, 4%, 10%, 15%
Unlicensed special on BAD list |
13.05.02 |
Dithranol pomade 0.4% |
Dithranol 0.4% w/w, salicylic acid 2%, emulsifying wax 25% , liquid paraffin to 100%
Unlicensed special on BAD list |
18 |
DMSA (succimer) capsules |
|
02.07.01 |
Dobutamine |
|
08.01.05 |
Docetaxel |
|
01.06.02 |
Docusate sodium |
Includes capsules and oral solution (Stimulant/softener)
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
05.03.01 |
Dolutegravir |
HIV infection only |
05.03.01 |
Dolutegravir, abacavir & lamivudine Triumeq® |
HIV infection only NHSE commissioning policy B06/p/a |
05.03.01 |
Dolutegravir/lamivudine Dovato® |
|
05.03.01 |
Dolutegravir/rilpivine Juluca® |
|
04.06 |
Domperidone |
|
04.11 |
Donepezil |
Alzheimers Disease
Dementia associated with Parkinsons disease or Lewy bodies - Priorities Committee Policy Statement 25
|
02.07.01 |
Dopamine |
|
05.03.01 |
Doravirine Pifeltro® |
For use in line with NHSE policy 190137P |
03.07 |
Dornase Alfa Pulmozyme® |
Cystic fibrosis - commissioned by NHS England |
11.06 |
Dorzolamide generic |
|
11.06 |
Dorzolamide 2% with timolol 0.5% Cosopt iMulti |
|
11.06 |
Dorzolomide 2% with Timolol 0.5% generic |
|
13.02.01 |
DoubleBase® |
Zerodouble is the lower cost alternative for prescribing in primary care. |
03.05.01 |
Doxapram Dopram® |
|
15.01.07 |
Doxapram |
|
02.05.04 |
Doxazosin |
Modified release tablets are NON-FORMULARY |
07.04.01 |
Doxazosin |
Modified release tablets are NON-FORMULARY |
04.03.01 |
Doxepin |
For dermatology use only - pruritus |
13.03 |
Doxepin Xepin® |
Second line on dermatology recommendation only |
08.01.02 |
Doxorubicin |
|
08.01.02 |
Doxorubicin Caelyx® |
|
05.01.03 |
Doxycycline |
|
05.04.01 |
Doxycycline |
Travel Prophylaxis - Private Prescription |
13.06.02 |
Doxycycline capsules |
|
13.02.02 |
Drapolene® cream |
NHS England low value medication
A prescription for the treatment of nappy rash should not routinely be offered in primary care as the condition is appropriate for self-care |
02.03.02 |
Dronedarone Multaq® |
Second-line option strictly in accordance with the criteria in NICE TA 197 |
04.06 |
Droperidol Xomolix® |
Prevention and treatment of post-operative nausea and vomting in paediatrics. |
06.01.02.03 |
Dulaglutide |
For type 2 diabetes |
04.03.04 |
Duloxetine |
Mental Health specialists only to initiate for depression/GAD.
|
04.07.03 |
Duloxetine |
|
07.04.02 |
Duloxetine |
Stress incontinence in women
|
19.06 |
DuoDerm Extra Thin 10cm x 10cm |
To aid debriding, promote granulation, occlusive barrier.
For light to medium exuding wounds ONLY. Ensure correct size is applied; overlap the wound by at least 2 cm . odour from dressing constituents can be a concern to patients.
Not suitable for infected wounds unless oberved frequently. Not indicated routinely on diabetic foot wounds - contact local diabetic/foot protection team for advice. |
19.06 |
DuoDerm Extra Thin 5cm x 10cm |
To aid debriding, promote granulation, occlusive barrier.
For light to medium exuding wounds ONLY. Ensure correct size is applied; overlap the wound by at least 2 cm . odour from dressing constituents can be a concern to patients.
Not suitable for infected wounds unless oberved frequently. Not indicated routinely on diabetic foot wounds - contact local diabetic/foot protection team for advice. |
19.06 |
DuoDerm Extra Thin 7.5cm x 7.5cm |
To aid debriding, promote granulation, occlusive barrier.
For light to medium exuding wounds ONLY. Ensure correct size is applied; overlap the wound by at least 2 cm . odour from dressing constituents can be a concern to patients.
Not suitable for infected wounds unless oberved frequently. Not indicated routinely on diabetic foot wounds - contact local diabetic/foot protection team for advice. |
13.05.03 |
Dupilumab Dupixent® |
NICE TA 534: Dupilumab for treating moderate to severe atopic dermatitis |
19.15 |
Durafiber Ag 10cm x 10cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 15cm x 15cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 2cm x 45cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 4cm x 10cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 4cm x 20cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 4cm x 30cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
19.15 |
Durafiber Ag 5cm x 5cm |
A highly absorbent, non-woven, sliver gelling fibre dressing. Use as a primary dressing for moderately to high exuding wounds where there is infection. |
08.01.05 |
Durvalumab Imfinzi® |
|
13.02.01 |
E45® |
Zerocream is a lower cost alternative for primary care prescribing |
07.02.02 |
Econazole Gyno-Pevaryl® |
|
09.01.03 |
Eculizumab Soliris® |
|
13.02.01 |
Eczmol® cream |
Contains 1% chlorhexidine. Can also be used as a soap substitute |
02.08.02 |
Edoxaban Lixiana® |
Stroke prevention in non-valvular AF
DVT and PE treatment and secondary prevention |
05.03.01 |
Efavirenz Sustiva® |
HIV infection only |
05.03.03.02 |
Elbasvir/grazoprevir Zepatier® |
|
08.01.05 |
Eltrectinib Rozlytrek® |
|
09.01.04 |
Eltrombopag Revolade® |
|
01.05 |
Eluxadoline Truberzi® |
|
13.02.01 |
Emollin® spray |
50:50 liquid paraffin/white soft paraffin aerosol spray |
06.01.02.03 |
Empagliflozin Jardiance▼® |
|
05.03.01 |
Emtricitabine Emtriva® |
HIV infection only |
05.03.01 |
Emtricitabine + tenofovir alafenamide Descovy® |
HIV infection |
05.03.01 |
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® |
HIV infection only |
13.02.01 |
Emulsifying Ointment BP |
|
02.05.05.01 |
Enalapril |
|
08.01.05 |
Encorafenib Braftovi® |
|
05.03.01 |
Enfuvirtide Fuzeon® |
HIV infection only |
02.08.01 |
Enoxaparin Clexane ® |
Prescribe by BRAND name
Continue the brand the patient has been initiated on. |
02.08.01 |
Enoxaparin (biosimilar) Inhixa® |
Prescribe by BRAND name
Continue the brand the patient has been initiated on. |
04.09.01 |
Entacapone |
|
05.03.03.01 |
Entecavir Baraclude® |
Chronic hepatitis B in line with NICE TA 153 |
15.01.02 |
Entonox® |
50% nitrous oxide, 50% oxygen |
08.02.02 |
Envarsus® Tacrolimus |
Second-line for the renal transplant (when other preparations have unacceptable side effects). Used under the advice of renal transplant specialists ONLY. |
08.03.04.02 |
Enzalutamide Xtandi® |
|
13.11 |
Eosin solution 2% w/v |
Included in BAD specials list 2014 |
13.02.01 |
Epaderm® |
Dermatology only in secondary care. Listed in DT as appliance. |
12.02.02 |
Ephedrine 0.5% and 1% nasal drops |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
02.07.02 |
Ephedrine hydrochloride injection |
|
13.02.01 |
Epimax® |
Epimax is a cost effective alternative to Diprobase cream |
08.01.02 |
Epirubicin |
|
02.02.03 |
Eplerenone tablets |
Left ventricular dysfunction (LVEF <40%) and clinical evidence of heart failure after recent myocardial infarction. NYHA class II CHF and left ventricular systolic dysfunction (LVEF <30%) in addition to standard optimal therapy. |
09.01.03 |
Epoetin alfa Eprex® |
|
09.01.03 |
Epoetin beta NeoRecormon® |
|
02.08.01 |
Epoprostenol Flolan® |
Information on restriction - Restricted to Neonatal unit, Surgery and Critical Care only
|
09.06.04 |
Ergocalciferol 300,000 units per ml |
|
07.01.01 |
Ergometrine maleate |
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
|
08.01.05 |
Eribulin Halaven® |
|
08.01.05 |
Erlotinib Tarceva® |
|
08.01.05 |
Erlotinib Tarceva® |
|
05.01.02.02 |
Ertapenem Invanz® |
Microbiology recommendation only |
06.01.02.03 |
Ertugliflozin Steglatro® |
|
05.01.05 |
Erythromycin Erymax® |
GUM only |
05.01.05 |
Erythromycin |
|
05.01.05 |
Erythromycin |
|
11.03.01 |
Erythromycin 0.5% |
Unlicensed |
13.06.02 |
Erythromycin tablets |
|
13.06.01 |
Erythromycin with zinc acetate Zineryt® |
|
04.03.03 |
Escitalopram |
Refer to MHRA and local advice concerning QT prolongation and dose restrictions |
02.04 |
Esmolol |
Critical care and theatres only |
01.03.05 |
Esomeprazole |
Includes tablets and capsules |
01.03.05 |
Esomeprazole injection |
For use by the neonatal and paediatric department only |
02.11 |
Etamsylate Dicynene® |
Information on restriction - Gynaecology use only
|
10.01.03 |
Etanercept Enbrel® |
Prescribe by brand name |
13.05.03 |
Etanercept (biosimilar) injection Benepali® |
Prescribe by brand name |
10.01.03 |
Etanercept biosimilar Benepali® |
Prescribe by brand name |
13.05.03 |
Etanercept injection Enbrel® |
Prescribe by brand name |
09.05.01.02 |
Etelcalcetide Parsabiv® |
|
05.01.09 |
Ethambutol |
|
18 |
Ethanol (alcohol) injection |
|
02.13 |
Ethanolamine Oleate |
|
08.03.01 |
Ethinylestradiol |
Oncology use only. High cost in primary care. |
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill TriRegol®, Logynon® |
Consilient brand = Triregol |
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®, Mercilon® |
Consilient brand = Gedarel 20/150 |
07.03.01 |
Ethinylestradiol 20mcg/Gestodene 75mcg |
Second line use
Millinette 20/75 is preferred brand for prescribing |
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg Lucette®, Dretine®, Yacella® |
Second line option |
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon® |
Consilient brand = Gedarel 30/150 |
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®, Femodene®,Sofiperla® |
Consilient brand = Millinette 30 |
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30®, Levest® |
Consilient brand = Rigevidon |
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin® |
|
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 500mcg Ovysmen®, Brevinor® |
|
07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique® |
Cliest has been discontinued July 2019 |
04.08.01 |
Ethosuximide |
Capsules are HIGH COST in primary care
MHRA advice on switching:
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
15.02 |
Ethyl Chloride Cryogesic® Spray |
Anaesthetics, A&E, surgery only |
15.01.01 |
Etomidate Hypnomidate® |
|
07.03.02.02 |
Etonorgestrel Nexplanon® |
Implant - only to be inserted and removed by trained doctor/nurse |
08.01.04 |
Etoposide |
|
08.01.04 |
Etoposide |
|
05.03.01 |
Etravirine Intelence® |
HIV infection only |
13.02.01 |
Eucerin® Intensive |
Contains 10% urea |
18 |
European Viper Venom Antivenom |
|
09.06.04 |
Evacal D3® |
Calcium carbonate 1500mg/colecalciferol 400 units |
08.01.05 |
Everolimus Afinitor® |
|
02.12 |
Evolocumab Repatha® |
primary hypercholesterolaemia or mixed dyslipidaemia |
13.02.01 |
Excetra® |
Cost effective alternative to Cetraben cream |
08.03.04.01 |
Exemestane |
|
06.01.02.03 |
Exenatide Byetta▼® |
Twice daily injection - type 2 diabetes |
06.01.02.03 |
Exenatide prolonged release Bydureon▼® |
Once weekly injection for type 2 diabetes |
19.13 |
Exufiber 10cm x 10cm |
For infected/heavily exudating wounds. Do NOT use on dry or low exudating wounds. Requires a secondary dressing. |
19.13 |
Exufiber 15cm x 15cm |
For infected/heavily exudating wounds. Do NOT use on dry or low exudating wounds. Requires a secondary dressing. |
19.13 |
Exufiber 2cm x 45cm |
Apply in a cavity wound or on shallow wounds. Should overlap the wound margins. |
19.13 |
Exufiber 4.5cm x 10cm |
Apply in a cavity wound or on shallow wounds. Should overlap the wound margins. |
19.13 |
Exufiber 4.5cm x 20cm |
Apply in a cavity wound or on shallow wounds. Should overlap the wound margins. |
19.13 |
Exufiber 4.5cm x 30cm |
Apply in a cavity wound or on shallow wounds. Should overlap the wound margins. |
19.13 |
Exufiber 5cm x 5cm |
For infected/heavily exudating wounds. Do NOT use on dry or low exudating wounds. Requires a secondary dressing. |
02.12 |
Ezetimibe Ezetrol® |
Third-line treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia where;
- Known statin intolerance
- Contraindication to statin.
|
10.01.04 |
Febuxostat Adenuric® |
Option if allopurinol contraindicated or not tolerated. Refer to local guidance on management of gout. |
02.06.02 |
Felodipine |
Second line option after amlodipine or if low dose required in elderly (2.5mg tablets) |
02.12 |
Fenofibrate |
Mixed dyslipidaemia unresponsive to statins |
04.07.02 |
Fentanyl |
Most cost effective brand in primary care is Mezolar Matrix |
15.01.04.03 |
Fentanyl |
|
04.07.02 |
Fentanyl sublingual tablets Abstral® |
Incident and breakthrough pain in opioid tolerant cancer patients not responding to usual rescue medications. Prescribe by brand name |
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Restricted to use in patients unable to receive Monofer® e.g. renal patients requiring doses of up to 1g to be given by an IV bolus and paediatrics
|
09.01.01.01 |
Ferric maltol Feraccru® |
Restricted to gastroenterology - only for the treatment of iron deficiency anaemia in adult patients with inflammatory bowel disease. |
09.01.01.01 |
Ferrous Fumarate |
|
09.01.01.01 |
Ferrous Sulphate |
|
03.04.01 |
Fexofenadine |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
20 |
Fibrin Sealant Evicel® |
Information on restriction - Urology - Partial nephrectomy surgery. ENT - pharyngeal resection, named surgeon only.
|
05.01.07 |
Fidaxomicin Dificlir® |
Under advice of microbiology only. |
09.01.06 |
Filgrastim |
Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost. |
06.04.02 |
Finasteride |
|
02.03.02 |
Flecainide |
|
02.03.02 |
Flecainide |
Liquid for use in infants and children unable to swallow tablets |
01.06.05 |
Fleet Phospho-soda® |
|
13.02.01 |
Flexitol® |
Contains 25% urea |
13.02.01 |
Flexitol® |
Contains 10% urea |
13.04 |
Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® |
|
13.04 |
Flucinolone Acetonide 0.00625% Synalar 1 in 4 Dilution® |
|
13.04 |
Flucinolone Acetonide 0.025% Synalar® |
|
05.01.01.02 |
Flucloxacillin |
|
05.02 |
Fluconazole |
Resistant candida, with specialist advice |
11.03.02 |
Fluconazole 0.2% eye drops |
Unlicensed |
05.02 |
Flucytosine Ancotil® |
|
08.01.03 |
Fludarabine Phosphate |
|
06.03.01 |
Fludrocortisone |
|
13.04 |
Fludroxycortide tape Haelan® |
|
15.01.07 |
Flumazenil |
|
18 |
Flumazenil injection |
|
12.01.01 |
Flumetasone 0.02% with clioquinol 1% ear drops |
Previously Locorten-Vioform |
11.04.01 |
Fluocinolone intravitreal implant Iluvien® |
Diabetic macular oedema NICE TA 301 |
11.08.02 |
Fluorescein Sodium Eye drops, injection |
|
11.04.01 |
Fluorometholone eye drops FML® |
Low potency |
08.01.03 |
Fluorouracil |
|
13.08.01 |
Fluorouracil 5% cream Efudix® |
|
04.03.03 |
Fluoxetine |
First line agent in general population
20mg capsules are the most cost-effective presentation for doses of 20mg, 40mg and 60mg.
Oral solution 20mg in 5ml can be used for patients with swallowing difficulties or if a 10mg dose is required. |
04.02.01 |
Flupentixol Depixol® |
|
04.03.04 |
Flupentixol Fluanxol® |
|
04.02.02 |
Flupentixol Decanoate Depixol® |
Psychiatry only |
04.02.02 |
Flupentixol Decanoate Depixol® Conc. |
Psychiatry only |
04.02.02 |
Flupentixol Decanoate Depixol® Low Volume |
Psychiatry only |
04.02.02 |
Fluphenazine decanoate injection Modecate® |
Modecate is going to be discontinued and will no longer be available after the end of 2018.
New patients should not be initiated on Modecate and existing patients will need to be identified and an alternative treament prescribed. |
10.01.01 |
Flurbiprofen tablets |
Ophthalmology initiation only |
08.03.04.02 |
Flutamide |
|
03.02 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
COPD 92/22 strength only – refer to COPD guidelines. Asthma step 4 or 5 BTS |
12.02.01 |
Fluticasone furoate nasal spray Avamys® |
Second-line corticosteroid for allergic rhinitis.
|
03.02 |
Fluticasone propionate Flixotide® |
MDI / Accuhaler |
13.04 |
Fluticasone Propionate Cutivate® |
Second Line - Dermatology and Paediatrics only |
03.02 |
Fluticasone propionate and formoterol Flutiform® |
Asthma only |
03.02 |
Fluticasone propionate and salmeterol Sirdupla®, Seretide®, Sereflo ® |
At high doses of Seretide, Accuhalers are significantly cheaper than MDIs and should be prescribed in preference to MDIs where possible.
Sirdupla and Sereflo - alternative combination inhaler for asthma only – prescribe by brand name. Note, only licensed for patients >18 years |
12.02.01 |
Fluticasone propionate nasal spray Flixonase® |
|
09.01.02 |
Folic Acid |
|
18 |
Fomepizole |
Ethylene glycol or methanol poisoning |
02.08.01 |
Fondaparinux Arixtra® |
For use in patients with a previous history of heparin induced thrombocytopenia (HIT) for thromboprophylaxis
Under advice of haematology for use in treatment of HIT (off-label use) |
13.07 |
Formaldehyde Veracur® |
NHS England low value medication
A prescription for the treatment of warts and verrucae should not routinely be offered in primary care as the condition is appropriate for self-care. |
03.01.01.01 |
Formoterol fumarate Atimos® Modulite |
|
03.01.01.01 |
Formoterol fumarate Easyhaler |
First line LABA for COPD. Dry powder device |
05.03.01 |
Fosamprenavir Telzir® |
HIV infection only |
04.06 |
Fosaprepitant Ivemend® |
NHSE funded chemotherpay supportive drug
Only for patients unable to take any oral antiemetics or with anticipatory nausea and vomiting. |
05.03.02.02 |
Foscarnet Sodium Foscavir® |
CMV retinitis |
05.01.07 |
Fosfomycin Fomicyt® |
Consultant microbiologist recommendation only- refer to PHT microguide |
05.01.07 |
Fosfomycin Monuril® |
Community multi-resistant Extended-spectrum Beta-lactamase (ESBL) E. coli UTI - on advice from microbiology.
Restricted prescribing as per Microguide or NICE prescribing guidance |
06.01.06 |
FreeStyle Libre flash glucose monitoring sensors |
See referral criteria on front page |
06.01.06 |
Freestyle Lite® |
Category 2 |
06.01.06 |
Freestyle Optium® |
Category 2 |
04.07.04.02 |
Fremanezumab Ajovy® |
|
A2.02.01.02 |
Fresubin® Jucy |
For those patients who cant tolerate milk based Aymes shakes |
08.03.04.01 |
Fulvestrant Faslodex® |
|
13.05.02 |
Fumaderm® |
Moderate to severe psoriasis- unlicensed |
02.02.02 |
Furosemide |
|
11.03.01 |
Fusidic Acid 1% |
Second line |
13.10.01.02 |
Fusidic Acid 2% cream Fucidin® |
|
04.07.03 |
Gabapentin |
Refer to chronic pain guidelines |
04.11 |
Galantamine |
Alzheimers Disease
Dementia associated with Parkinsons disease or Lewy bodies - Priorities Committee Policy Statement 25
Cost effective brands for prescribing in primary care are Galazemic or Gazylan XL
|
04.07.04.02 |
Galcanezumab Emgality® |
|
19.20 |
Gamgee Drug Tariff (pink) 500g |
Used to absorb large amounts of exudate. Not to be used as primary dressing. If used in leg management always pad OUTSIDE the bandage to maintain adequate pressures (if compression to the leg).
Can be cut to size. |
05.03.02.02 |
Ganciclovir Cymevene® |
CMV infections only - intravenous |
11.03.03 |
Ganciclovir 0.15% ophthalmic gel Virgan® |
|
01.01.02 |
Gaviscon Advance |
Peptac or Acidex Advance is a cost effective alternative in primary care
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
01.01.02 |
Gaviscon Infant |
|
08.01.05 |
Gefitinib Iressa® |
|
09.02.02.02 |
Gelatin Gelofusine® |
|
08.01.03 |
Gemcitabine |
|
08.01.05 |
Gemtuzumab ozogamicin Mylotarg® |
|
05.01.04 |
Gentamicin |
refer to PHT Drug Therapy Guideline |
05.01.04 |
Gentamicin |
via nebuliser for non-CF bronchiectasis - refer to shared care agreement |
12.01.01 |
Gentamicin |
|
11.03.01 |
Gentamicin 0.3% |
|
11.03.01 |
Gentamicin 1.5% |
Unlicensed |
08.01.05 |
Gilteritinib Xospata® |
|
12.03.05 |
Glandosane® |
ACBS |
08.02.04 |
Glatiramer Acetate Copaxone® |
|
05.03.03.02 |
Glecaprevir/Pibrentasvir |
|
06.01.02.01 |
Gliclazide |
plain tablets - not MR |
06.01.04 |
Glucagon GlucaGen® HypoKit |
|
18 |
Glucagon GlucaGen® Hypokit |
Beta-blocker overdose |
06.01.04 |
GlucoGel® |
|
06.01.06 |
GlucoMen Areo® |
Category 1 acceptable |
06.01.06 |
Glucomen LX sensors® |
Category 2 |
06.01.01.03 |
GlucoRx CarePoint |
|
06.01.01.03 |
GlucoRx FinePoint |
|
06.01.01.03 |
GlucoRx Lancets |
|
06.01.06 |
GlucoRx Nexus® |
Category 1 acceptable |
06.01.01.03 |
GlucoRx Safety |
Only for patients unable to self administer |
09.02.02.01 |
Glucose intravenous injection/infusion |
5%,10%,, 20%, 50% |
06.01.06 |
Glucose test strips |
Refer to local guidance on preferred products. |
01.06.02 |
Glycerol (Glycerin) |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care
|
11.99.99.99 |
Glycerol 15% eye drops |
|
02.06.01 |
Glyceryl Trinitrate |
|
02.06.01 |
Glyceryl Trinitrate GTN |
300mcg tablets are cheaper than 500mcg in primary care |
02.06.01 |
Glyceryl Trinitrate |
|
02.06.01 |
Glyceryl Trinitrate |
|
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
|
07.04.04 |
Glycine |
|
03.01.04 |
Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler® |
LABA+LAMA. Refer to COPD guidelines |
03.01.02 |
Glycopyrronium Seebri Breezhaler® |
LAMA in capsule for inhalation via Breezhaler device. Refer to COPD guidelines |
20 |
Glycopyrronium oral solution 5mg in 5ml |
For hypersalivation
Unlicensed special listed in Drug Tariff
Paediatrics only |
15.01.03 |
Glycopyrronium bromide |
|
13.12 |
Glycopyrronium bromide 0.05% w/v in water |
for iontophoresis
Unlicensed special on BAD list and in Drug Tariff |
13.12 |
Glycopyrronium bromide 2% in cetomacrogol cream |
Unlicensed special on BAD list and in Drug Tariff |
01.05.03 |
Golimumab Simponi® |
|
10.01.03 |
Golimumab Simponi® |
|
06.05.01 |
Gonadorelin HRF® |
Secondary care only |
06.07.02 |
Goserelin |
|
08.03.04.01 |
Goserelin Zoladex® |
|
08.03.04.02 |
Goserelin Zoladex® |
|
08.03.04.02 |
Goserelin Zoladex® LA |
|
04.06 |
Granisetron |
For chemotherapy induced nausea and vomiting |
02.05.03 |
Guanethidine Monosulphate Ismelin® |
Pain Clinic only |
04.04 |
Guanfacine Intuniv® |
CAMHS Shared care agreement for Hampshire will be available on iDOCs |
13.05.03 |
Guselkumab Tremfya® |
|
04.02.01 |
Haloperidol |
|
04.02.02 |
Haloperidol Haldol Decanoate® |
Psychiatry only |
04.09.03 |
Haloperidol |
|
02.08.01 |
Heparin 10units per ml injection Hepsal® |
for use in paediatric patients only where being administered by community nurses
|
02.08.01 |
Heparin Calcium injection |
|
02.08.01 |
Heparin Sodium injection |
|
14.04 |
Hepatitis A vaccine |
Havrix, Avaxim, Vaqta, Vaqta Paediatric
For adults and children travelling to at risk areas - prescribe by brand name and check appropriate dose. |
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine |
Twinrix, Ambirix
For people travelling to at risk areas |
14.04 |
Hepatitis A vaccine with typhoid vaccine |
Hepatyrix, ViATIM
For adults travelling to at risk areas |
14.04 |
Hepatitis B vaccine |
Engerix B, HbvaxPRO, Fendrix
For people at increased risk of exposure to hepatitis B virus, at increased risk of complications of hepatitis B or post potential exposure to hepatitis B virus (including infants born to mothers carrying hepatitis B).
|
13.11.02 |
Hibitane Obstetric® |
|
11.99.99.99 |
Holoclar® |
Ex vivo expanded autologous human corneal cells containing stem cells |
11.05 |
Homatropine eye drops |
|
09.02.02.02 |
Human albumin solution |
|
14.04 |
Human papilloma virus vaccine Gardasil® |
For use in routine immunisation programme - 12-13 years old, girls only |
10.03.01 |
Hyaluronidase Hyalase® |
Gynaecology - for perineal pain/scarring |
02.05.01 |
Hydralazine |
|
06.03.01 |
Hydrocortisone Alkindi® |
Paediatric use only |
06.03.02 |
Hydrocortisone |
|
13.04 |
Hydrocortisone |
|
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
06.03.02 |
Hydrocortisone sodium phosphate Efcortesol® |
Secondary Care Initiated |
06.03.02 |
Hydrocortisone sodium succinate Solu-Cortef® |
|
13.04 |
Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® |
|
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
|
12.01.01 |
Hydrocortisone 1% with gentamicin 0.3% ear drops Gentisone® HC |
|
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort® |
|
13.04 |
Hydrocortisone 1%, Urea 10% and Lactic Acid 5% Calmurid HC® |
|
01.05.02 |
Hydrocortisone 10% rectal foam Colifoam® |
|
12.03.01 |
Hydrocortisone 2.5mg mucoadhesive buccal tablets |
|
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® |
|
06.03.02 |
Hydrocortisone acetate oral suspension |
Unlicensed special
Paediatrics only |
13.04 |
Hydrocortisone Butyrate Locoid® |
|
11.04.01 |
Hydrocortisone sodium phosphate 3.35mg/mL eye drops Softacort® |
|
19.04 |
Hydrofilm 10cm x 12.5cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 10cm x 15cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 10cm x 25cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 12cm x 25cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 15cm x 20cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 20cm x 30cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
19.04 |
Hydrofilm 6cm x 7cm |
Dry, non infected wounds; retention of lines; fixation of secondary dressings. NB: Management of IV sites - refer to local guidlines |
13.11.06 |
Hydrogen Peroxide 1% Crystacide® |
Superficial bacterial skin infection |
13.11.06 |
Hydrogen Peroxide Solution BP |
Solution 6% (20 vols)
|
20 |
Hydroquinone, hydrocortisone and tretinoin Pigmanorm® |
Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w
Unlicensed in the UK. On BAD specials list for melasma (maximum 6 months treatment). |
13.02.01 |
Hydrous ointment (oily cream) |
|
09.01.02 |
Hydroxocobalamin (vitamin B12) |
|
18 |
Hydroxocobalamin for infusion Cyanokit® |
Cyanide poisoning |
08.01.05 |
Hydroxycarbamide |
|
10.01.03 |
Hydroxychloroquine tablets |
|
11.08.01 |
Hydroxyethylcellulose unit dose drops Minims® Artificial Tears |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
03.04.01 |
Hydroxyzine |
For dermatology use only in secondary care
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
01.02 |
Hyoscine Butylbromide Buscopan® |
Includes tablets and injection (for syringe drivers) |
04.06 |
Hyoscine hydrobromide Scopoderm TTS® |
Licensed for motion sickness but used for other unlicensed indications e.g. palliative care
NHS England low value medication
A prescription for the treatment of motion sickness should not routinely be offered in primary care as the condition is appropriate for self-care |
04.06 |
Hyoscine Hydrobromide |
|
04.06 |
Hyoscine Hydrobromide Kwells |
NHS England low value medication
A prescription for the treatment of motion sickness should not routinely be offered in primary care as the condition is appropriate for self-care |
15.01.03 |
Hyoscine hydrobromide |
|
19.21 |
Hypafix® tape |
2.5cm, 5cm, 10cm |
11.08.01 |
Hypromellose 0.3% eye drops and preservative-free eye drops |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
06.06.02 |
Ibandronic Acid |
150mg tablet (monthly)
Use as per osteoporosis guidelines |
06.06.02 |
Ibandronic Acid |
Oncology only- adjuvant treatment of post-menopausal breast cancer (off-licence) |
06.06.02 |
Ibandronic Acid |
Post-menopausal osteoporosis if oral biphosphonates unsuitable or not tolerated |
08.01.05 |
Ibrutinib Imbruvica® |
|
07.01.01.01 |
Ibuprofen Pedea® injection |
Information on restriction - Neonatal Unit only
|
10.01.01 |
Ibuprofen |
Oral suspension sugar free 100mg in 5ml, Tablets 200mg, 400mg , 600mg
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
10.03.02 |
Ibuprofen gel |
Knee and hand OA, 5% and 10%
Fenbid is most cost effective brand in primary care
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
10.01.01 |
Ibuprofen SR Brufen Retard® |
Rheumatology, orthopaedics and Pain Clinic only |
13.05.01 |
Ichthammol |
Ichthopaste, Icthaband |
19.16 |
Ichthopaste 7.5cm x 6m |
Chronic eczema/dermatitis where occlusion is indicated. Zinc paste and ichthammol.
Ensure any residue is removed before re-bandaging. Patch testing is required prior to use. To be applied as per manufacturer's guidance. Not as a primary dressing or as a patch. |
08.01.02 |
Idarubicin Zavedos® |
|
02.08 |
Idarucizumab Praxbind® |
Information on restriction - Specific reversal agent for dabigatran. On consultant haematologist advice only in cases of life-threatening bleeding or where emergency surgery is necessary.
|
08.01.05 |
Idelalisib Zydelig® |
|
08.01.01 |
Ifosfamide |
|
08.01.05 |
Imatinib |
|
04.03.01 |
Imipramine |
Alternative to amitriptyline for peripheral neuropathic pain in adults - refer to chronic pain guideline |
04.07.03 |
Imipramine |
Alternative to amitriptyline in peripheral neuropathic pain in adults - refer to chronic pain guidelines |
13.07 |
Imiquimod Aldara® |
External genital and perianal warts - GUM only
Small superficial basal cell carcinomas (sBCCs) - on dermatologist recommendation only |
19.15 |
Inadine 5cm x 5cm |
Non-adherent dressing impregnated with 10% povidone-iodine. colour changes will indicates when to change dressing.
Management and prevention of infection in ulcers, minor burns and minor traumatic skin injuries. Not effective in medium to heavy exudate. |
19.15 |
Inadine 9.5 x 9.5 |
Non-adherent dressing impregnated with 10% povidone-iodine. colour changes will indicates when to change dressing.
Management and prevention of infection in ulcers, minor burns and minor traumatic skin injuries. Not effective in medium to heavy exudate. |
02.02.01 |
Indapamide |
2.5mg tablets
Sustained release preparation (Natrilix 1.5mg SR) are NON-FORMULARY |
05.03.01 |
Indinavir Crixivan® |
HIV infection only |
20 |
Indocyanine Green |
Surgical dye |
10.01.01 |
Indometacin |
|
07.04.01 |
Indoramin |
|
14.04 |
Infanrix hexa® |
Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).
For use in routine immunisation programme at 8 weeks old, 12 weeks old, 16 weeks old |
14.04 |
Infanrix IPV® |
Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)
For use in routine immunisation programme - pre-schoool booster |
14.04 |
Infanrix-IPV+Hib® |
Diphtheria (D), tetanus (T), pertussis (acellular component) (Pa), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed)
|
A2.01 |
Infatrini Peptisorb |
See faltering growth guideline |
A2.01 |
Infatrini® |
Energy Dense Feed
Should not be started in primary care without specialist advice
|
01.05.03 |
Infliximab Remicade® |
Severe active Crohns disease in line with NICE TA 187, Acute exacerbation of sever active ulcerative colitis NICE TA 163, Moderately to severelty active ulcerative colitis NICE TA 329. Prescribe by brand name |
10.01.03 |
Infliximab Remicade® |
Prescribe by brand name |
01.05.03 |
Infliximab (biosimilar) Inflectra® |
Severe active Crohns disease in line with NICE TA 187, Acute exacerbation of sever active ulcerative colitis NICE TA 163, Moderately to severelty active ulcerative colitis NICE TA 329. Prescribe by brand name |
01.05.03 |
Infliximab (biosimilar) Remsima® |
Prescribe by brand name |
13.05.03 |
Infliximab (biosimilar) for infusion Remsima® |
Prescribe by brand name |
13.05.03 |
Infliximab (biosimilar) for infusion Inflectra® |
Prescribe by brand name |
10.01.03 |
Infliximab biosimilar Remsima® |
Prescribe by brand name |
10.01.03 |
Infliximab biosimilar Inflectra® |
Prescribe by brand name |
13.05.03 |
Infliximab for infusion Remicade® |
|
14.04 |
Influenza Vaccine Intanza® |
Refer to Wesex PGDs for inclusion criteria |
14.04 |
Influenza vaccine seasonal,intramuscular |
For adults over 65 years or in at risk groups, given annually as part of national programme, and pregnant women |
14.04 |
Influenza vaccine intranasal Fluenz Tetra® |
For children aged 2-8 (including school years R, 1-4) |
08.01.05 |
Inotuzumab ozogamicin Besponsa® |
NICE TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
06.01.01.01 |
Insulin Humulin® S |
|
06.01.01.01 |
Insulin Actrapid® |
|
06.01.01.01 |
Insulin Insuman® Rapid |
|
06.01.01.01 |
Insulin Aspart NovoRapid® |
1.6ml cartridges (PumpCart) are for Accucheck Insight insulin pumps only |
06.01.01.01 |
Insulin aspart Fiasp® |
Mealtime insulin - different formulation to Novorapid. |
06.01.01.02 |
Insulin degludec Tresiba® |
100units/ml strength |
06.01.01.02 |
Insulin degludec 200 units/ml Tresiba® |
Concentrated insulin 200 units/ml in prefilled pen ONLY. For people requiring larger doses, to reduce injection volume. |
06.01.01.02 |
Insulin Detemir Levemir® |
|
06.01.01.02 |
Insulin Glargine Lantus® |
|
06.01.01.02 |
Insulin Glargine Toujeo® |
Only initiate with advice from a diabetic consultant or diabetes specialist nurse
Concentrated insulin 300 units/ml in a prefilled pen only
For patients with large insulin requirements due to insulin resistance - to reduce injection volumes |
06.01.01.02 |
Insulin Glargine biosimilar |
First choice for patients needing a new basal analogue insulin |
06.01.01.01 |
Insulin Glulisine Apidra® |
|
06.01.01.01 |
Insulin Lispro 100 units/ml Humalog® |
NB Kwikpen has 2 strengths - 100units/ml and 200units/ml.
|
06.01.01.01 |
Insulin Lispro 200 units/ml Humalog® |
200units/ml
Concentrated insulin available in pre-filled pen ONLY |
06.01.01.01 |
Insulin porcine Hypurin® Porcine Neutral |
|
08.02.04 |
Interferon Alfa IntronA® |
|
10.02 |
Interferon beta-1a Avonex®, Rebif® |
|
10.02.01 |
Interferon beta-1b Extavia® |
|
09.03 |
Intralipid 20% |
|
19.07 |
IntraSite Conformable 10cm x 10cm |
Primary indicated for the treatment of necrotic and sloughy wounds, e.g. leg ulcers, pressure ulcers and non-infected diabetic foot ulcers. Not suitable for infected or heavily exudating wounds. Secondary dressings required. |
19.07 |
IntraSite Conformable 10cm x 20cm |
Primary indicated for the treatment of necrotic and sloughy wounds, e.g. leg ulcers, pressure ulcers and non-infected diabetic foot ulcers. Not suitable for infected or heavily exudating wounds. Secondary dressings required. |
19.07 |
IntraSite Conformable 10cm x 40cm |
Primary indicated for the treatment of necrotic and sloughy wounds, e.g. leg ulcers, pressure ulcers and non-infected diabetic foot ulcers. Not suitable for infected or heavily exudating wounds. Secondary dressings required. |
07.03.04 |
Intra-uterine Contraceptive Devices Flexi-T® 300 |
|
07.03.04 |
Intra-uterine Contraceptive Devices GyneFix® |
|
07.03.04 |
Intra-uterine Contraceptive Devices Multiload® 375 |
|
07.03.04 |
Intra-uterine Contraceptive Devices Nova-T® 380 |
|
07.03.04 |
Intra-uterine levonorgestrel Kyleena® |
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
Effective up to 5 years |
07.03.02.03 |
Intra-uterine Progestogen Only System Jaydess® |
Second line if Mirena not suitable.
Licensed for contraception only.
Effective up to 3 years |
07.03.02.03 |
Intra-uterine Progestogen Only System Levosert® |
|
06.02.02 |
Iodine and Iodide |
Hospital use only |
19.15 |
Iodoflex 10g |
Cadexomer dressing with iodine. For the treatment of chronic exuding wounds. Not to be used on dry necrotic tissue.
Can apply up to 50g per dressing change, cover with a secondary dressing and change when paste is saturated. do NOT exceed 150g Iodoflex in 1 week, or more than 3 months single course of treatment. |
19.15 |
Iodoflex 5g |
Cadexomer dressing with iodine. For the treatment of chronic exuding wounds. Not to be used on dry necrotic tissue.
Can apply up to 50g per dressing change, cover with a secondary dressing and change when paste is saturated. do NOT exceed 150g Iodoflex in 1 week, or more than 3 months single course of treatment. |
08.01.05 |
Ipilimumab Yervoy® |
|
03.01.02 |
Ipratropium bromide |
MDI
Nebules |
03.01.04 |
Ipratropium bromide with salbutamol Combivent® |
Nebules |
02.05.05.02 |
Irbesartan |
Option for hypertension in diabetes |
08.01.05 |
Irinotecan Hydrochloride |
|
09.01.01.01 |
Iron and Folic Acid Pregaday® |
|
09.01.01.02 |
Iron Dextran CosmoFer® |
|
09.01.01.02 |
Iron isomaltoside Monofer® |
Preferred IV iron preparation at PHT.
Refer to IV Iron Drug Therapy Guideline |
09.01.01.02 |
Iron Sucrose Venofer® |
For patients on haemodialysis only |
08.01.05 |
Isatuximab Sarclisa® |
|
15.01.02 |
Isoflurane |
|
13.02.01 |
Isomol® |
Isomol is a cost effective alternative to Doublebase Gel |
05.01.09 |
Isoniazid |
|
06.01.01.02 |
Isophane Insulin Hypurin® Porcine Isophane |
|
06.01.01.02 |
Isophane Insulin Insulatard® |
|
06.01.01.02 |
Isophane Insulin Humulin® I |
|
06.01.01.02 |
Isophane Insulin Insuman® Basal |
|
02.07.01 |
Isoprenaline injection |
|
02.06.01 |
Isosorbide Mononitrate |
Asymmetric dosage |
02.06.01 |
Isosorbide Mononitrate MR |
25mg & 50mg MR preparation - prescribe as Capsules
60mg MR preparation - Prescribe as Chemydur 60XL tablets
Nocturnal angina and in cases of non-compliance.
|
13.06.01 |
Isotretinoin Isotrex® gel |
|
13.06.02 |
Isotretinoin |
|
13.06.01 |
Isotretinoin with erythromycin Isotrexin® |
|
01.06.01 |
Ispaghula husk granules |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
05.02 |
Itraconazole |
Restricted prescribing as per Microguide or NICE prescribing guidance |
02.06.03 |
Ivabradine |
NYHA Class II-IV stable chronic heart failure in line with NICE TA 267 |
02.06.03 |
Ivabradine |
Primary Care - only for initiation in stable angina where beta blockers contraindicated or not tolerated
Second Line for patients with contraindication or intolerance to betablockers or suboptimal response to diltiazem. Initiation by consultant cardiologist, diabetologist, respiratory physician, MOPRS only.) |
03.07 |
Ivacaftor |
As per NHS England commissioning statement Cystic Fibrosis Modulator Therapies 19013P |
13.06 |
Ivermectin cream Soolantra® |
|
20 |
Ivermectin tablets |
Scabies, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone. |
08.02.04 |
Ixazomib Ninlaro® |
|
13.05.03 |
Ixekizumab injection Taltz® |
|
14.04 |
Japanese Encephalitis Vaccine Ixiaro® |
Private Supply only |
19.07 |
KerraLite Cool 6cm x 6cm |
Consider when pain is a significant factor.
For use on chronic wounds, painful wounds, skin conditions such as leg ulcers, radiation therapy damage, burns and scalds. May be used on low-exuding and non-exuding wounds to assist in autolytic debridement by hydration of necrotic and sloughy tissue and for absorption of exudate. |
19.07 |
KerraLite Cool 8.5cm x 12cm |
Consider when pain is a significant factor.
For use on chronic wounds, painful wounds, skin conditions such as leg ulcers, radiation therapy damage, burns and scalds. May be used on low-exuding and non-exuding wounds to assist in autolytic debridement by hydration of necrotic and sloughy tissue and for absorption of exudate. |
15.01.01 |
Ketamine injection |
Ketamine 100mg in 10ml pre-filled syringe - DCCQ only for emergency use (unlicenced) |
13.09 |
Ketoconazole 2% shampoo |
NHS England low value medication
A prescription for treatment of dandruff should not routinely be offered in primary care as the condition is appropriate for self-care |
13.10.02 |
Ketoconazole cream |
NHSE low value medication
A prescription for the treatment of ringworm or athlets foot should not routinely be offered in primary care as the condition is appropriate for self-care |
06.01.06 |
Ketones test strips |
Recommendation to self-test for ketones must be maade by the diabetes specialist sevice. |
10.01.01 |
Ketoprofen MR |
Inflammatory arthritis |
11.08.02 |
Ketorolac Acular® |
|
15.01.04.02 |
Ketorolac |
|
03.04.01 |
Ketotifen Zaditen® |
Paediatrics only |
19.12 |
Kliniderm Foam Silicone Border adhesive 10cm x 10m |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone Border adhesive 10cm x 20cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone Border adhesive 12.5cm x 12.5cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge. |
19.12 |
Kliniderm Foam Silicone Border adhesive 15cm x 15cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge. |
19.12 |
Kliniderm Foam Silicone Border adhesive 15cm x 20cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge. |
19.12 |
Kliniderm Foam Silicone Border adhesive 7.5cm x 7.5cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge. |
19.12 |
Kliniderm Foam Silicone non-adhesive 10cm x 10cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone non-adhesive 10cm x 20cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone non-adhesive 15cm x 15cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone non-adhesive 20cm x 20cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.12 |
Kliniderm Foam Silicone non-adhesive 5cm x 5cm |
For use on moderately exuding wounds. Foam dressing should be left in place for up to 7 days. Exudate will be visible but change dressing when strike through is 1 cm from edge.
Foam dressings should not be used for pressure relief. |
19.11 |
Kliniderm Superabsorbent Dressing Kliniderm |
to replace Vliwasorb Pro Sizes available, in packs of 10 unless stated otherwise:
10cm x 10cm |
10cm x 15cm |
10cm x 20cm |
20cm x 20cm (pack 15) |
20cm x 30cm |
20cm x 40cm
|
|
19.23 |
K-Lite 10cm x 4.5cm |
second-line use after Ultra-Lite |
13.08.01 |
LA Roche-Posay Anthelios XL SPF 50+ Cream® |
NHS England low value medicine
A prescription for sun protection should not routinely be offered in primary care as this is suitable for self-care.
Sun protection may be prescribed as per ACBS recommendations: Approved for skin protection against UV radiation in abnormal cutaneous photosensitivity. This includes genetic disorders, photodermatoses, vitiligo from radiotherapy and chronic or recurrent herpes simplex labialis. |
02.04 |
Labetalol |
|
04.08.01 |
Lacosamide Vimpat ® |
Refractory epilepsy only
MHRA advice on switching:
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors.
|
01.06.04 |
Lactulose solution |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
05.03.01 |
Lamivudine Epivir® |
HIV infection, hepatitis B |
05.03.01 |
Lamivudine Zeffix® |
HIV infection, hepatitis B |
04.08.01 |
Lamotrigine |
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
03.04.03 |
Lanadelumab Takhzyro® |
|
08.03.04.03 |
Lanreotide Somatuline Autogel® |
Reduction of secretions from pancreatic/enterocutaneous fistula if more than 4 weeks treatment is required(off-licence) |
08.03.04.03 |
Lanreotide Somatuline Autogel® |
Red for new patients
Amber shared care for existing patients only
|
08.03.04.03 |
Lanreotide Somatuline® LA |
Red for new patients
Amber shared care for existing patients only
|
01.03.05 |
Lansoprazole |
Orodispersible tablets are restricted to patients unable to swallow capsules
NHS England low value medication
A prescription for mild infrequent indegestion and heartburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
09.05.02.02 |
Lanthanum carbonate Fosrenol ® |
Red for renal dialysis patients |
08.01.05 |
Lapatinib Tyverb® |
|
09.08.01 |
L-Arginine 5g in 10ml injection |
Unlicensed
Paediatrics only |
08.01.05 |
Larotrectinib Vitrakin® |
|
11.06 |
Latanoprost |
First line |
11.06 |
Latanoprost 0.005% with Timolol 0.5% generic |
|
11.06 |
Latanoprost 50micrograms/mL + timolol 5mg/mL Fixapost® |
|
11.06 |
Latanoprost Preservative Free Monopost® |
First choice where a preservative-free prostaglandin analogue is required |
19.20 |
LBF Sterile No Sting Barrier Film 5 x 1ml |
|
19.20 |
LBF Sterile No Sting Barrier Film 5 x 2ml |
|
05.03.03.02 |
Ledipasvir and Sofosbuvir Harvoni® |
|
10.01.03 |
Leflunomide tablets |
For the treatment of BK viraemia and nephropathy in renal transplant recipients |
10.01.03 |
Leflunomide tablets |
NOT FOR RENAL INDICATIONS |
08.02.04 |
Lenalidomide Revlimid® |
|
09.01.06 |
Lenograstim Granocyte® |
Commissioned by NHS England for neutropenia according to Trust Guidelines. Use product with lowest acquisition cost. |
08.01.05 |
Lenvatinib Lenvima® |
|
02.06.02 |
Lercanidipine |
Second line option after amlodipine - hypertension only |
05.03.02.02 |
Letermovir Prevymis® |
|
08.03.04.01 |
Letrozole |
|
19.20 |
Leukostrip 6.4cm x 76mm |
Available on FP10, more cost-effective than Steri-strip. |
06.07.02 |
Leuprorelin |
|
08.03.04.02 |
Leuprorelin Acetate Lutrate® 1 month depot 3.75mg |
|
08.03.04.02 |
Leuprorelin Acetate Lutrate® 3 month depot 22.5mg |
|
08.03.04.02 |
Leuprorelin Acetate Prostap® 3 |
|
08.03.04.02 |
Leuprorelin Acetate Prostap® SR |
|
05.05.02 |
Levamisole oral |
Paediatrics only - available from special order manufacturers or importers |
20 |
Levamisole 50mg tablets |
Roundworm infections |
04.08.01 |
Levetiracetam |
Includes tablets and oral solution
MHRA advice on switching:
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
15.02 |
Levobupivacaine Chirocaine® |
|
04.09.01 |
Levodopa, carbidopa and entacapone Stalevo® Stanek® |
Cost effective brand for prescribing in primary care is Stanek |
05.01.12 |
Levofloxacin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
11.03.01 |
Levofloxacin |
Eye drops
Preservative free eye drops
|
13.03 |
Levomenthol Menthoderm, Dermacool |
0.5%, 1% and 2%
Menthoderm is the preferred product at PHT |
04.02.01 |
Levomepromazine (methotrimeprazine) |
Prescribe as 25mg tablets - these can be divided to provide 6.25mg or 12.5 mg oral doses.
6mg tablets are only available as an unlicensed special at HIGH COST in primary care. |
07.03.05 |
Levonorgestrel |
1.5mg stat tablet up to 72 hours post UPSI |
07.03.02.01 |
Levonorgestrel tablets Norgeston® |
|
20 |
Levosimendan for infusion |
Critical care only - refer to Drug Therpay Guideline |
06.02.01 |
Levothyroxine tablets |
|
15.02 |
Lidocaine |
|
15.02 |
Lidocaine 10% spray |
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine 4% solution Laryngojet |
|
11.07 |
Lidocaine 4% with fluorescein 0.25% unit dose eye drops Minims® |
|
15.02 |
Lidocaine 5% and Phenylephrine 0.5% |
|
15.02 |
Lidocaine 5% ointment |
|
15.02 |
Lidocaine medicated plaster 5% Versatis® |
For acute pain associated with fractured ribs - maximum two weeks treatment (off-licence indication). SECONDARY CARE ONLY.
Neuropathic pain associated with herpes zoster infection (post-herpetic neuralgia). PRIMARY AND SECONDARY CARE.
|
15.02 |
Lidocaine with Adrenaline Xylocaine® |
|
20 |
Lidocaine/adrenaline/tetracaine (LAT) |
Paediatrics only. |
15.02 |
Lidocaine2% with Chlorhexidine 0.25% Instillagel® |
|
15.02 |
Lignocaine |
|
19.20 |
LimbO waterproof leg protector |
Available as slim, normal and large build, standard leg and short leg. |
01.06.07 |
Linaclotide Constella® |
Moderate to severe irritable bowel syndrome with constipation as recommended in NICE CG 61 |
06.01.02.03 |
Linagliptin Trajenta▼® |
|
05.01.07 |
Linezolid |
On microbiologist advice only - refer to PHT Microguide |
06.02.01 |
Liothyronine sodium injection |
Restricted use to patients:
- Requiring treatment of myxoedema coma
- With gut failure (also requiring parenteral nutrition) requiring treatment of hypothyroidism
|
06.02.01 |
Liothyronine sodium tablets |
To be initiated by NHS secondary care only for approved indications
Note HIGH COST in primary care |
08.01.05 |
Liposomal cytarabine-daunorubicin Vyxeos® |
|
13.02.01 |
Liquid paraffin 50% white soft paraffin 50% ointment 50:50 |
|
01.06.03 |
Liquid Paraffin and Magnesium Hydroxide Emulsion BP |
Avoid use in the elderly |
01.06.04 |
Liquid Paraffin and Magnesium Hydroxide Emulsion BP |
Avoid use in the elderly
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
06.01.02.03 |
Liraglutide Saxenda® |
(only Saxenda® brand): Weight management in adults according to NICE TA664 |
06.01.02.03 |
Liraglutide Victoza® |
Once daily injection for type 2 diabetes |
04.04 |
Lisdexamfetamine Elvanse® |
Children - CAMHS initiation only for ADHD refractory to methylphenidate
CAMHS Shared care agreement for Hampshire will be available on iDOCs
Adults - diagnosis and treatment initiation via Hampshire ADHD service (provided by Surrey and Borders Partnership NHSFT)
Awaiting shared care guidelines |
02.05.05.01 |
Lisinopril |
|
04.02.03 |
Lithium Carbonate Priadel® |
Prescribe by brand name
Green For Portsmouth CCG patients
|
04.02.03 |
Lithium Carbonate Camcolit ® |
Prescribe by brand name
Green For Portsmouth CCG patients
|
04.02.03 |
Lithium Carbonate Liskonum® |
Prescribe by brand name
Green For Portsmouth CCG patients
|
04.02.03 |
Lithium Citrate Li-Liquid® |
Prescribe by brand name
Green For Portsmouth CCG patients
|
04.02.03 |
Lithium Citrate Priadel®Liquid |
Prescribe by brand
Green For Portsmouth CCG patients
|
11.04.02 |
Lodoxamide eye drops Alomide® |
Ophthalmology recommendation only |
04.03.01 |
Lofepramine |
|
04.10.03 |
Lofexidine BritLofex® |
Substance Misuse Services only |
08.01.01 |
Lomustine |
|
01.04.02 |
Loperamide |
Includes capsules and syrup
NHS England low value medicine
A prescription for treatment of acute diarrhoes should not routinely be offered in primary care as the condition is appropriate for self care |
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
HIV infection only |
03.04.01 |
Loratadine |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
04.01.02 |
Lorazepam |
|
04.01.02 |
Lorazepam |
Short term use only |
15.01.04.01 |
Lorazepam |
|
08.01.05 |
Lorlatinib Lorviqua® |
|
02.05.05.02 |
Losartan |
|
11.04.01 |
Loteprednol eye drops Lotemax® |
Low potency |
03.07 |
Lumacaftor/Ivacaftor Orkambi® |
As per NHS England commissioning statement Cystic Fibrosis Modulator Therapies 190137P |
09.01.04 |
Lusutrombopag Mulpleo® |
|
08.01.05 |
Lutetium (177Lu) oxodotretide Lutathera® |
NICE TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
05.01.03 |
Lymecycline generic |
|
13.06.02 |
Lymecycline capsules |
|
18 |
Macrogol '3350' Klean-Prep® |
For gut decontamination for overdose with agents not bound by activated charcoal (e.g. iron & lithium). |
01.06.04 |
Macrogol oral powder Laxido®, Laxido Paediatric®, Cosmocol® |
For chronic constipation or faecal impaction |
01.06.05 |
Macrogols Klean-Prep®, Moviprep® |
|
11.08.01 |
Macrogols eye drops Systane® |
Eye drops, Unit dose drops, Systane Balance |
09.05.01.03 |
Magnesium Aspartate Magnaspartate® |
10mmol magnesion per sachet |
09.05.01.03 |
Magnesium glycerophosphate Neomag® |
4mmol magnesium per tablet |
09.05.01.03 |
Magnesium Glycerophosphate |
Unlicensed special - only to be used if Magnaspartate is not suitable or not tolerated. |
01.06.04 |
Magnesium Hydroxide Mixture BP |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
09.05.01.03 |
Magnesium Sulphate |
|
13.10.05 |
Magnesium Sulphate Paste BP |
|
01.01.01 |
Magnesium Trisilicate Mixture BP |
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
13.10.04 |
Malathion 0.5% aqueous solution Derbac-M® |
NHS England low value medication
A prescription for the treatment of head lice should not routinely be offered in primary care as the condition is suitable for self-care |
02.02.05 |
Mannitol 10% and 20% |
|
05.05.01 |
Mebendazole |
NHS England low value medicine
Treatment of threadworms is suitable for self-care and mebendazole can be sold over the counter for children and adults over the age of 2 years.
Prescribing in line with NICE antibiotic guidelines for children aged 6 months to 2 years only |
01.02 |
Mebeverine tablets |
Note oral suspension is available but is high cost in primary care
£187.00 for 300ml (DT February 2017) |
19.15 |
Medihoney Antibacterial Honey Apinate 1.9cm x 30cm |
Non-adherent, non-absorbent, protease modulating matrix, sterile. Contains calcium and antibacterial honey. |
19.15 |
Medihoney Antibacterial Honey Apinate 10cm x 10cm |
Non-adherent, non-absorbent, protease modulating matrix, sterile. Contains calcium and antibacterial honey. |
19.15 |
Medihoney Antibacterial Medical Honey 20g |
Useful on sinus wounds. indicated for infected or critically colonised wounds. Can be effective if malodour present, as a desloughing agent or in the treatment of necrotic wounds. |
19.15 |
Medihoney Antibacterial Medical Honey 50g |
Useful on sinus wounds. indicated for infected or critically colonised wounds. Can be effective if malodour present, as a desloughing agent or in the treatment of necrotic wounds. |
13.02 |
medihoney barrier cream 50g MediHoney® |
2nd line for nappy rash (if improvement is not seen with current first line, Derma S). Under the advice of tissue viability ONLY
On advice of the tissue viability team. Medihoney may be prescribed for patients with severe moisture damage |
19.15 |
Medihoney HCS 11cm x 11cm |
An all-in-one dressing that combines 63% Medihoney in a hydrogel dressing with superabsorbent polymer. |
19.15 |
Medihoney HCS 11cm x 11cm Adhesive |
An all-in-one dressing that combines 63% Medihoney in a hydrogel dressing with superabsorbent polymer.
The adhesive dressing does not require a secondary dressing. For dry to moderately exudating wounds. |
19.15 |
Medihoney HCS 6cm x 6cm |
An all-in-one dressing that combines 63% Medihoney in a hydrogel dressing with superabsorbent polymer. |
19.15 |
Medihoney Tulle Dressing 10cm x 10cm |
For superficial wounds. Strong woven dressings impregnated with antibacterial honey, sterile. |
06.04.01.02 |
Medroxyprogesterone Acetate Provera® |
|
07.03.02.02 |
Medroxyprogesterone acetate Sayana Press® |
13-weekly subcutaneous injection
May be self-administered following training by HCP.
Women who self-administer will require sharps container and completed healthcare waste collection referral form to request collection by local council. |
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
12-weekly intramuscular injection |
08.03.02 |
Medroxyprogesterone Acetate Provera® |
|
10.01.01 |
Mefenamic Acid |
Dysmenorrhoea |
05.04.01 |
Mefloquine Lariam® |
Travel Prophylaxis - Private Prescription |
08.03.02 |
Megestrol Acetate Megace® |
|
04.01.01 |
Melatonin Paediatrics |
CAMHS / Community Paediatrics only if sleep hygiene measures have failled.
2mg m/r (Circadin) first line, but off license. Unlicensed tablets/capsules second line - a brand name must be specified. Kidnaps oral suspension 1mg in 1ml (unlicensed) if liquid required |
10.01.01 |
Meloxicam |
|
08.01.01 |
Melphalan |
|
04.11 |
Memantine |
Moderate and severe Alzheimers Disease.
Dementia associated with Parkinsons disease or Lewy bodies - Priorities Committee Policy Statement 25
Shared Care Guideline awaited
|
09.06.06 |
Menadiol Sodium Phosphate |
|
06.01.06 |
Mendor Discreet Cartridge® |
Category 2 |
14.04 |
Meningococcal A, C, W135, and Y conjugate vaccine |
Menveo, Nimenrix
For use in routine immunisation programme - 14 years old (year 9)
Asplenia/splenic dysfunction - refer to guidance |
14.04 |
Meningococcal group B Vaccine Bexsero® |
For use in routine immunisation programme at 8 weeks, 16 weeks and 1 year old
Asplenia/splenic dysfunction - refer to guidance |
14.04 |
Menitorix® |
Haemophilus type b and Meningococcal group C conjugate vaccine
For use in routine childhood vaccination programme at age 1 year
Asplenia/splenic dysfunction - refer to guidance |
03.08 |
Menthol and Eucalyptus Inhalation BP 1980 |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
15.02 |
Mepivacaine Scandonest Plain® |
For use as a intra-cervical block to faciliate insertion of intra-uterine devices only. |
03.04.02 |
Mepolizumab Nucala® |
Only to be initiated in tertiary specialist commissioned centres.
|
08.01.03 |
Mercaptopurine |
|
01.05.03 |
Mercaptopurine tablets |
Crohn's disease - unlicensed indication |
05.01.02.02 |
Meropenem Meronem® |
Second line for adults with febrile neutropenia |
01.05.01 |
Mesalazine Asacol® |
Prescribe by brand name. Includes tablets, foam enema and suppositories
In primary care the most cost effective brand is Octasa |
01.05.01 |
Mesalazine Pentasa® |
Prescribe by brand name. Includes tablets and retention enema |
01.05.01 |
Mesalazine Salofalk® |
Prescribe by brand name. Includes granules (sachets) and retention enema 2g in 59ml |
01.05.01 |
Mesalazine m/r tablets Octasa® |
Prescribe by brand name |
01.05.01 |
Mesalazine m/r tablets Mezavant® XL |
Second-line mesalazine prep - prescribe by brand name - once daily dosing |
13.02.02 |
Metanium® ointment |
NHS England low value medication
A prescription for the treatment of nappy rash should not routinely be offered in primary care as the condition is appropriate for self-care |
02.07.02 |
Metaraminol injection |
Anesthetics and Critical Care only
unlicensed
|
06.01.02.02 |
Metformin |
If liquid is required prescribe metformin oral solution sugar free 500mg in 5ml (150ml) as listed in Drug Tariff |
06.01.02.02 |
Metformin & pioglitazone Competact® |
For patients established on both agents |
06.01.02.02 |
Metformin Hydrochloride Glucophage® SR, Sukkarto® SR |
Second line - only if standard metformin not tolerated in an adequate dose.
Preferred product in primary care is Sukkarto SR tablets - prescribe by brand name |
04.10.03 |
Methadone 1mg/ml |
Substance Misuse services only |
04.10 |
Methadone Hydrochloride |
Substance Misuse Services only |
05.01.13 |
Methenamine Hippurate Hiprex® |
|
01.05.03 |
Methotrexate |
Crohn's dsease - unlicensed indication
Tablets 2.5mg
Nordimet - prefilled pen
Metoject PEN - prefilled pen |
08.01.03 |
Methotrexate |
|
10.01.03 |
Methotrexate |
Tablets 2.5mg
Nordimet - prefilled pen
Metoject PEN - prefilled pen
|
13.05.03 |
Methotrexate |
Tablets 2.5mg
Nordimet - prefilled pen
Metoject PEN - prefilled pen |
13.05.02 |
Methoxypsoralen |
PUVA – unlicensed |
13.08.01 |
Methyl-5-Aminolevulinate Metvix® |
Secondary Care Only (Dermatology only - photodynamic therapy for actinic keratosis |
01.06.01 |
Methylcellulose Celevac® |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
02.05.02 |
Methyldopa |
for use in pregnancy |
01.06.06 |
Methylnaltrexone Relistor® |
For opioid induced constipation where there has been inadequate response to standard laxatives. On specialist palliative care recommendation only in primary care |
04.04 |
Methylphenidate |
Children - CAMHS initiation only
CAMHS Shared care agreement for Hampshire will be available on iDOCs
Adults - diagnosis and treatment initiation via Hampshire ADHD service (provided by Surrey and Borders Partnership NHSFT)
Awaiting shared care guidelines |
04.04 |
Methylphenidate Hydrochloride MR |
Children - CAMHS initiation only
Prefered product is Matoride XL
CAMHS Shared care agreement for Hampshire will be available on iDOCs
Adults - diagnosis and treatment initiation via Hampshire ADHD service (provided by Surrey and Borders Partnership NHSFT)
Awaiting shared care guidelines |
06.03.02 |
Methylprednisolone |
Methylprednisolone acetate (Depo-Medrone) - Green
Methylprednisolone sodium succinate injection - Amber under protocol from specialist for MS exacerbations |
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
Depo-Medrone may be used by any of the following routes: intramuscular, intra-articular, periarticular, intrabursal, intralesional or into the tendon sheath. |
10.01.02.02 |
Methylprednisolone acetate with lidocaine Depo-Medrone® with Lidocaine |
|
18 |
Methylthioninium chloride Proveblue® |
Methaemoglobinaemia |
20 |
Methylthioninium chloride Proveblue® |
Ifosfamide-induced encephalopathy (off-licence)
Vasopressor in septic shock (off-licence) |
04.06 |
Metoclopramide |
|
02.02.01 |
Metolazone |
Metolazone is now discontinued in the UK and is only available as an unlicensed special or import. |
02.04 |
Metoprolol |
|
02.04 |
Metoprolol Tartrate Betaloc® |
|
05.01.11 |
Metronidazole |
|
05.01.11 |
Metronidazole |
|
07.02.02 |
Metronidazole Zidoval® |
|
13.10.01.02 |
Metronidazole 0.75% cream Rozex® |
Rosacea |
13.10.01.02 |
Metronidazole 0.75% gel Anabact® Rozex® |
Anabact - malodorous fungating tumours and ulcers
Rozex - rosacea |
06.07.03 |
Metyrapone Metopirone® |
Secondary Care only |
20 |
Mexiletine capsules |
|
05.02.04 |
Micafungin Mycamine® |
On microbiology advice only |
07.02.02 |
Miconazole Gyno-Daktarin® |
Vaginal capsule (Ovule) 1.2g single dose
|
12.03.02 |
Miconazole Daktarin® |
NHS England low value medication
A prescription for the treatment of oral thrush should not be routinely offered in primary care as the condition is appropriate for self-care. |
13.10.02 |
Miconazole nitrate 2% cream |
NHSE low value medication
A prescription for the treatment of ringworm or athlets foot should not routinely be offered in primary care as the condition is appropriate for self-care |
06.01.01.03 |
Microdot Max Safety |
Only for patients unable to self administer |
15.01.04.01 |
Midazolam |
|
04.01.01 |
Midazolam injection |
by subcutaneous injection for symptom control in palliative care |
04.08.02 |
Midazolam Oromucosal Solution Buccolam® |
Please prescribe using brand name in primary care |
02.07.02 |
Midodrine tablets |
|
08.01.05 |
Midostaurin Rydapt® |
|
07.01.02 |
Mifepristone Mifegyne® |
|
02.01.02 |
Milrinone injection Primacor® |
|
02.05.01 |
Minoxidil |
Renal Unit only |
07.04.02 |
Mirabegron Betmiga® |
Refer to local OAB guidelines |
04.03.04 |
Mirtazapine |
Second line agent |
07.01.01 |
Misoprostol tablets |
|
08.01.02 |
Mitomycin |
|
11.99.99.99 |
Mitomycin C intra-ocular injection |
Unlicensed |
08.01.02 |
Mitoxantrone (Mitozantrone) |
|
15.01.05 |
Mivacurium Mivacron® |
Critical Care only |
14.04 |
MMRVaxPRO® |
Measles, Mumps and Rubella vaccine (live)
For use in routine immunisation programme at 1 year old and preschool booster |
06.01.06 |
Mobile Test Cassette® |
Category 2 |
04.03.02 |
Moclobemide |
Specialist initiation only |
04.04 |
Modafinil |
Hypersomnolence associated with Parkinson's disease (off-licence)
Excessive sleepiness associated with narcolepsy |
A2.03.02 |
Modulen IBD® |
|
13.04 |
Mometasone Furoate 0.1% Elocon® |
|
12.02.01 |
Mometasone furoate nasal spray |
Second-line corticosteroid |
03.03.02 |
Montelukast |
|
04.07.02 |
Morphine sulfate |
Includes MR capsules (Zomorph), sachets, injection, oral solution |
20 |
Morphine sulfate 10mg in 10ml Intrasite gel |
Acute painful skin reactions due to radiotherapy |
12.03.04 |
Mouthwash Solution tablets |
|
05.01.12 |
Moxifloxacin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
02.05.02 |
Moxonidine |
Consultant recommendation only |
A2.05.02 |
Multi-thick® |
|
09.06.07 |
Multivitamin preparations Abidec® |
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption.
Patients suitable for Healthy start vitamins between the ages of 6months and 4years. |
09.06.07 |
Multivitamin preparations Dalivit® |
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption.
Patients suitable for Healthy start vitamins between the ages of 6months and 4years. |
12.02.03 |
Mupirocin 2% ointment Bactroban Nasal® |
For MRSA only |
13.10.01.01 |
Mupirocin 2% ointment Bactroban® |
|
08.02.01 |
Mycophenolate Mofetil |
|
08.02.01 |
Mycophenolate Mofetil |
|
08.02.01 |
Mycophenolate Sodium Myfortic® |
Transplant patients only. Prescribe by BRAND name |
20 |
Mydricaine No.1 and No.2 injection |
|
06.01.01.03 |
Mylife Lancets |
|
06.01.01.03 |
Mylife Penfine Classic |
|
06.01.06 |
MyLife Pura® |
Category 1 acceptable |
10.01.01 |
Nabumetone |
Rheumatology only |
06.07.02 |
Nafarelin |
|
02.06.04 |
Naftidrofuryl |
|
01.06.06 |
Naldemedine Rizmoic® |
|
04.10.01 |
Nalmefene Selincro® |
Refer to local pathway |
01.06.06 |
Naloxegol Moventig® |
For opioid induced constipation where there has been inadequate response to standard laxatives. |
15.01.07 |
Naloxone |
|
18 |
Naloxone injection |
Opioid overdose |
04.10.01 |
Naltrexone Adepend® |
Alcohol dependence |
04.10.03 |
Naltrexone Nalorex® |
opioid dependence |
04.10 |
Naltrexone Hydrochloride Opizone® |
Substance Misuse services only |
06.04.03 |
Nandrolone Deca-Durabolin® |
Secondary Care only |
10.01.01 |
Naproxen |
|
11.03.01 |
Natamycin 5% eye drops |
Unlicensed |
02.04 |
Nebivolol |
5mg tablets only (2.5mg tablets are available but are significantly more expensive than 5mg tablets - for a 2.5mg dose use half a 5mg tablet)
For use in hypertension in patients intolerant of other beta-blockers. Hypertension and Cardiology specialities only.
|
A2.01 |
Neocate LCP |
Amino Acid Formula
Second line option
First line for severe reactions/anaphylactic reactions/reactions to breast milk
Refer to secondary care |
15.01.06 |
Neostigmine |
|
10.02.01 |
Neostigmine tablets |
|
15.01.06 |
Neostigmine with glycopyrronium |
|
11.08.02 |
Nepafenac Nevanac® |
Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients - full course to be supplied by hospital. |
08.01.05 |
Neratinib Nerlynx ® |
|
04.06 |
Netupitant and Palonosetron Akynzeo® |
For prevention of chemotherapy induced nausea and vomiting only - refer to CINV guidelines
|
13.02.01 |
Neutrogena® Dermatological Cream |
NPF |
05.03.01 |
Nevirapine Viramune® |
HIV infection only |
02.06.03 |
Nicorandil |
Third line agent for angina |
04.10.02 |
Nicotine Replacement Therapy |
Includes all formulations and brands
Primary Care - as part of smoking cessation programme.
Secondary care - refer to PHT NRT guideline (only a limited range of NRT products are stocked at PHT) |
02.06.02 |
Nifedipine Apidine XL®, Adipine MR |
|
02.06.02 |
Nifedipine Adalat® Retard |
Off-licence use in premature labour - maternity services only.
Refer to Trust guidelines |
02.06.02 |
Nifedipine Adalat® LA |
30mg & 60mg MR tablets. Once daily dosage. Prescribe as brand 'Adalat LA'. |
02.06.02 |
Nifedipine Coracten® XL |
Once daily dose |
02.06.02 |
Nifedipine Coracten® SR |
Twice daily dosage |
02.06.02 |
Nifedipine Adalat® Retard |
|
07.01.03 |
Nifedipine capsules |
Maternity services only for premature labour - refer to guideline |
08.01.05 |
Nilotinib Tasigna® |
|
02.06.02 |
Nimodipine Nimotop® |
|
03.11 |
Nintedanib Ofev® |
|
03.11 |
Nintedanib Vargatef® |
|
08.01.05 |
Nintedanib Vargatef® |
|
08.01.05 |
Niraparib Zejula® |
|
04.01.01 |
Nitrazepam |
Short term use only |
05.01.13 |
Nitrofurantoin |
Suspension is HIGH COST in primary care |
05.01.13 |
Nitrofurantoin Macrobid® |
Twice daily dosage, refer to local management of infection guidance |
15.01.02 |
Nitrous oxide |
|
08.02.04 |
Nivolumab Opdivo® |
|
01.03.01 |
Nizatidine |
For use during rantidine shortage only in patients who require treatment with a H2 antagonist
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
07.03.01 |
Nomegestrol acetate and beta estradiol Zoely® |
For initiation only by a specialist doctor in sexual health |
19.20 |
Non-woven fabric swab 7.5cm x 7.5cm Sterile |
Used for general purpose swabbing and cleansing. |
02.07.02 |
Noradrenaline acid tartrate injection norepinephrine |
Anaesthetics and critical care only |
06.04.01.02 |
Norethisterone |
|
07.03.02.01 |
Norethisterone Noriday® |
|
07.03.02.01 |
Norethisterone Micronor® |
|
08.03.02 |
Norethisterone |
|
07.03.02.02 |
Norethisterone enantate Noristerat® |
8 weekly injection |
14.05.01 |
Normal Human Immunoglobulin |
National demand management programme applies |
04.03.01 |
Nortriptyline |
Alternative to amitriptyline for peripheral neuropathic pain in adults - refer to chronic pain guideline
Note HIGH COST compared to amitriptyline |
04.07.03 |
Nortriptyline |
Alternative to amitriptyline for peripheral neuropathic pain in adults
Note HIGH COST in primary care compared to amitriptyline |
19.20 |
Nurse It dressing Pack |
Pair of powder-free latex vinyl gloves, 7 non-woven swabs, 1 compartment tray, disposable forceps, laminate paper sterile field, large apron, paper towel and white polythene disposable bag. |
10.02 |
Nusinersen Spinraza® |
|
A2.05.02 |
Nutilis Clear® |
|
A2.05.02 |
Nutilis® Powder |
|
A2.01 |
Nutramigen 1 with LGG® |
Cows Milk Protein Allergy
First Line Agent
Extensively Hydrolysed formula |
A2.01 |
Nutramigen 2 with LGG® |
Cows Milk Protein Allergy
Extensively Hydrolysed Formula
First line agent |
A2.01 |
Nutramigen Puramino ® |
Amino Acid Formula
First line for severe reactions/ anaphylactic reactions/ reactions to breast milk
Refer to secondary care |
A2.01 |
Nutriprem 2 |
For pre term infants
Follow discharge information - review at 6 months corrected age
Powder should be prescribed - ready made liquid for exceptional circumstances only (immunocompromised patients)
|
12.03.02 |
Nystatin oral suspension Nystan® |
Prescribe as Nystan brand |
13.10.02 |
Nystatin with Chlorhexidine cream Nystaform® |
|
01.09.01 |
Obeticholic acid Ocaliva® |
|
08.02.03 |
Obinutuzumab Gazyvaro ® |
|
08.02.04 |
Ocrelizumab Ocrevus® |
|
11.08.02 |
Ocriplasmin Jetrea® |
|
08.03.04.03 |
Octreotide Sandostatin Lar® |
Red for new patients
Amber shared care for existing patients only
|
08.03.04.03 |
Octreotide Sandostatin® |
Red for new patients
Amber shared care for existing patients only
|
08.03.04.03 |
Octreotide Olatuton LAR® |
|
18 |
Octreotide injection |
Sulphonylurea overdose |
06.04.01.01 |
Oestrogen only HRT gel Oestrogel |
|
06.04.01.01 |
Oestrogen only HRT patch Estradot, Evorel |
|
06.04.01.01 |
Oestrogen only HRT tablet Elleste-Solo |
Elleste Solo 1 and 2mg tablets
|
06.04.01.01 |
Oestrogens for HRT Sandrena® |
|
06.04.01.01 |
Oestrogens for HRT FemSeven® |
|
06.04.01.01 |
Oestrogens for HRT FemSeven® Conti |
|
06.04.01.01 |
Oestrogens for HRT Indivina® |
|
06.04.01.01 |
Oestrogens for HRT Elleste-Duet Conti® |
HRT Continous COmbined |
06.04.01.01 |
Oestrogens for HRT Angeliq® |
HRT Continous Combined
Only for women unable to tolerate other options |
07.02.01 |
Oestrogens, Topical Ovestin® |
Estriol 0.1% cream |
07.02.01 |
Oestrogens, Topical Vagifem® |
|
07.02.01 |
Oestrogens, Topical Estring® |
|
07.02.01 |
Oestrogens, Topical Gynest® |
Estriol 0.01% cream |
08.02.03 |
Ofatumumab Arzerra® |
|
05.01.12 |
Ofloxacin |
Restricted prescribing as per Microguide or NICE prescribing guidance |
11.03.01 |
Ofloxacin Eye drops Exocin® |
Severe bacterial infections
|
01.07.03 |
Oily phenol injection BP |
|
04.02.01 |
Olanzapine |
|
04.02.01 |
Olanzapine 10mg injection |
Only for use in accordance with rapid tranquilisation guidelines |
08.02.04 |
Olaparib Lynparza® |
|
12.01.03 |
Olive Oil Ear Drops |
NHS England low value medication
A prescription for the removal of earwax should not routinely be offered in primary care as the condition is appropriate for self-care |
11.04.02 |
Olopatadine eye drops Opatanol® |
|
01.05.01 |
Olsalazine tablets |
Tablets only |
03.04.02 |
Omalizumab Xolair® |
Severe persistent asthma with important allergic component in line with NICE TA 278. Adults and children over 6 years. Chronic spontaneous urticaria NICE TA 339 |
05.03.03.02 |
Ombitasvir/ paritaprevir/ ritonavir Viekirax® |
|
02.12 |
Omega-3-Acid Ethyl Esters Omacor® |
Information on restriction - Dermatology only - polymorphic light eruption.
Not for hypertriglyceridaemia or secondary prevention following myocardial infarction.
|
02.12 |
Omega-3-Marine Triglycerides Maxepa® |
Information on restriction - Dermatology only - polymorphic light eruption.
Not for hypertriglyceridaemia or secondary prevention following myocardial infarction. |
01.03.05 |
Omeprazole |
Avoid 40mg capsules in primary care (2x20mg is more cost effective)
NHS England low value medication
A prescription for mild infrequent indegestion and heartburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
01.03.05 |
Omeprazole Losec® |
Dispersible tablets for paediatrics only |
01.03.05 |
Omeprazole IV |
As per Trust guideline |
06.01.01.03 |
Omnican Fine |
Only 32 gauge |
06.01.01.03 |
Omnican Lance Soft Lancets |
|
04.06 |
Ondansetron |
Zofran MELTS are non formulary |
06.01.06 |
One Touch Select Plus® |
Category 1 preferred |
06.01.06 |
One Touch Verio ® |
Category 2 |
04.09.01 |
Opicapone Ongentys® |
Second-line after Entacapone following consultant clinician decision. |
06.01.06 |
Oral glucose tolerance test Rapilose® OGTT |
Diabetes Centre only - alternative to Polycal. |
09.02.01.02 |
Oral Rehydration Salts |
Rapolyte is most cost effective brand in primary care
NHS England low value medicine
A prescription for treatment of acute diarrhoes should not routinely be offered in primary care as the condition is appropriate for self care |
04.05.01 |
Orlistat |
|
04.09.02 |
Orphenadrine |
Orphenadrine tablets have been discontinued. An oral solution 50mg in 5ml is still available. |
05.03.04 |
Oseltamivir Tamiflu® |
|
08.02.04 |
Osimertinib Tagrisso |
|
08.01.05 |
Oxaliplatin |
|
20 |
Oxandrolone tablets 2.5 mg |
Unlicensed
Paediatrics only |
04.08.01 |
Oxcarbazepine Trileptal® |
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
11.07 |
Oxybuprocaine unit dose eye drops Minims® |
|
07.04.02 |
Oxybutynin |
Standard (non-modified release) tablets are not suitable for the elderly, especially if frail
Avoid liquid - unlicensed specials are HIGH COST in primary care |
07.04.02 |
Oxybutynin Hydrochloride Kentera® |
Primary care only
Option for people who cannot tolerate oral antimuscarinics (NICE CG 171) |
04.07.02 |
Oxycodone |
Palliative care second line if intolerant of morphine. Option for post operative pain if morphine causes hallucinations (acute pain team only - to be supplied as TTO if necessary but not to be continued in primary care).
Most cost effective brands in primary care are Shortec (IR) and Longtec (MR)/ Oxeltra (MR) |
04.07.02 |
Oxycodone |
Option for post-operative pain in enhanced recovery pathways |
04.07.02 |
Oxycodone/naloxone Targinact® |
Consultant gastroenterologist only for patients with opioid induced intestinal failure requiring parenteral nutrition. Not for general prescribing in severe pain. |
05.01.03 |
Oxytetracycline |
First line for acne |
13.06.02 |
Oxytetracycline tablets |
|
07.01.01 |
Oxytocin Syntocinon® |
|
09.06.02 |
Pabrinex® IM and IV |
Parenteral vitamins B and C for rapid correction of severe depletion or malabsorption |
08.01.05 |
Paclitaxel |
|
08.01.05 |
Paclitaxel - Albumin Bound Formulation Abraxane® |
|
08.03.04.01 |
Palbociclib Ibrance® |
Approved in accordance with NICE TA495, in combination with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. |
04.02.02 |
Paliperidone palmitate Trevicta® |
3-monthly depot
Southern Health NHS FT and Solent NHS Trust psychiatrists only |
04.02.02 |
Paliperidone palmitate Xeplion® |
1-monthly depot
Southern Health NHS FT and Solent NHS Trust psychiatrists only |
05.03.05 |
Palivizumab Synagis® |
Commissioned by NHSE according to JCVI and PHE guidance |
01.09.04 |
Pancreatin Creon® 10000 |
|
01.09.04 |
Pancreatin Pancrex® V |
For use in patients requiring administration via NG tubes only |
01.09.04 |
Pancreatin Creon® 40000 |
|
01.09.04 |
Pancreatin Creon® Micro |
|
01.09.04 |
Pancreatin Creon® 25000 |
|
01.09.04 |
Pancreatin Nutrizym® |
|
15.01.05 |
Pancuronium bromide |
|
08.01.05 |
Panitumumab Vectibix® |
|
08.01.05 |
Panobinostat Farydak® |
|
04.07.02 |
Papaveretum |
Severe pain |
20 |
Papaverine hydrochloride injection |
|
04.07.01 |
Paracetamol |
Mild to moderate pain
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
04.07.01 |
Paracetamol and codeine Co-codamol 8/500 |
Mild to moderate pain
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
04.07.01 |
Paracetamol and codeine Co-codamol 30/500 |
Severe pain. Most cost effective brand in primary care is Zapain |
04.07.01 |
Paracetamol and dihydrocodeine |
Mild to moderate pain
NHS England low value medication
A prescription for the treatment of minor conditions associated with pain, discomfort and mild fever should not routinely be offered in primary care as the condition is appropriate for self-care. (e.g aches and sprains, headache, period pain, back pain). |
04.07.01 |
Paracetamol IV Perfalgan® |
|
04.08.02 |
Paraldehyde Rectal Soln |
Paediatrics only, unlicensed special |
09.06.07 |
Paravit-CF |
Fat-soluble vitamin supplements for use when recommended by specialist in patients with cystic fibrosis. |
15.01.04.02 |
Parecoxib Dynastat® |
Short term use for post-operative pain as an adjunct to opioid analgesia where oral and rectal administration is not possible (Acute Pain Consultant only)
Post-operative ileus (colorectal ERP). |
09.03 |
Parenteral Nutrition (TPN or PN) |
Seek specialist advice on prescribing |
09.06.04 |
Paricalcitol Zemplar® |
Existing shared care patients may continue to get supplies via the GP |
04.03.03 |
Paroxetine |
Not first line agent. More frequent withhdrawal reactions. Do not exceed recommended dose. See CSM Warnings
|
09.02.01.01 |
Patiromer Valtassa® |
|
08.01.05 |
Pazopanib Votrient® |
|
14.04 |
Pediacel® |
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)
|
08.01 |
Pegaspargase Oncaspar® |
|
08.02.04 |
Peginterferon Alfa Pegasys® |
|
10.02.01 |
Peginterferon beta 1a Plegridy® |
|
08.01.05 |
Pembrolizumab Keytruda® |
|
08.01.03 |
Pemetrexed |
|
10.01.03 |
Penicillamine tablets |
|
18 |
Penicillamine tablets |
|
05.04.08 |
Pentamidine Isetionate Pentacarinat® |
|
07.04.03 |
Pentosan polysulfate sodium capsules Elmiron® |
|
20 |
Pentoxifylline tablets |
Alcoholic hepatitis - unlicensed use |
01.02 |
Peppermint Oil Mintec® |
Preferred brand in primary care |
01.02 |
Peppermint Oil Colpermin® |
Preferred brand in primary care is Mintec |
01.01.02 |
Peptac |
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
04.08.01 |
Perampanel Fycompa® |
Consultant neurologist only.
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
06.01.06 |
Performa Test Strips® |
Category 1 preferred |
02.05.05.01 |
Perindopril erbumine or tert-butylamine |
|
13.10.04 |
Permethrin 5% Lyclear® Dermal Cream |
for scabies and crablice |
08.01.05 |
Pertuzumab Perjeta® |
|
04.07.02 |
Pethidine |
Severe pain |
04.03.02 |
Phenelzine Nardil® |
Psychiatry only |
04.08.01 |
Phenobarbital |
Includes tablets and elixir.
Unlicensed alcohol-free liquid formulations may be prescribed in paediatrics.
MHRA Advice on switching:
Category 1: ensure patient is maintained on a specific manufacturer's product. |
13.11.05 |
Phenol 2% w/w in compound zinc paste BP |
Inlcuded on BAD specials list 2014 |
02.05.04 |
Phenoxybenzamine Hydrochloride |
Hypertension in phaeochromocytoma |
05.01.01.01 |
Phenoxymethylpenicillin |
|
02.05.04 |
Phentolamine Rogitine®, Regitin® |
Critical Care only |
18 |
Phentolamine injection |
|
11.05 |
Phenylephrine hydrochloride unit dose eye drops Minims® |
|
02.07.02 |
Phenylephrine injection |
|
04.07.03 |
Phenytoin |
|
04.08.01 |
Phenytoin |
Includes capsules, tablets, chewable tablets and suspension.
MHRA Advice on switching:
Category 1: ensure patient is maintained on a specific manufacturer's product.
|
04.08.02 |
Phenytoin Injection |
|
03.09.01 |
Pholcodine Linctus, BP |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
09.05.02.01 |
Phosphate Polyfusor® |
|
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
|
01.06.04 |
Phosphates (Rectal) |
|
09.06.06 |
Phytomenadione Konakion® MM |
|
09.06.06 |
Phytomenadione Konakion® MM Paediatric |
Can also be administered by mouth for high INRs in patients on warfarin. |
18 |
Phytomenadione Vitamin K1 |
|
01.06.05 |
Picolax® sodium picosulfate with magnesium citrate |
|
11.06 |
Pilocarpine |
|
12.03.05 |
Pilocarpine hydrochloride Salagen® |
|
13.05.03 |
Pimecrolimus 1% cream Elidel® |
Second line after topical steroids for moderate atopic eczema, especially face and neck - NICE TA 82. Not for children under 2 years |
04.02.01 |
Pimozide Orap® |
|
06.01.02.03 |
Pioglitazone Actos® |
|
06.01.02.03 |
Pioglitazone and Metfomin Competact® |
For patients established on both agents |
05.01.01.04 |
Piperacillin and Tazobactam |
Refer to Microguide |
04.02.02 |
Pipotiazine Palmitate Piportil® Depot |
Psychiatry only |
04.08.01 |
Piracetam Nootropil® |
|
20 |
Pirenzepine tablets |
|
03.11 |
Pirfenidone Esbriet® |
|
05.01.01.05 |
Pivmecillinam Selexid® |
|
08.01.02 |
Pixantrone |
|
04.07.04.02 |
Pizotifen |
|
01.06.05 |
Plenvu® |
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) Prevenar 13® |
For use in routine immunisation programme, at 8 weeks old, 16 weeks old and 1 year old.
Additional vaccine for individuals with underlying medical conditions (under 2 years of age) |
14.04 |
Pneumococcal polysaccharide vaccine (23-valent) |
For use in routine immunisation programme at age 65
Additional vaccine for individuals with underlying medical conditions (from 2 years of age) |
13.07 |
Podophyllotoxin Condyline® |
GUM only |
13.07 |
Podophyllotoxin Warticon® |
GUM only |
08.01.05 |
Polatuzumab vedotin Polivy® |
|
11.03.01 |
Polihexanide 0.02% |
Unlicensed |
14.04 |
Poliomyelitis Vaccine Live (oral) |
|
06.01.06 |
Polycal® |
Secondary Care Only |
19.20 |
Polyfield Nitrile Patient Pack Sterile dressing pack |
Sterile dressing pack containing powder-free nitrile gloves, laminate sheet, 7 non-woven swabs, towel, apron and disposable bag. |
14.04 |
Polysaccharide Typhoid Vaccine |
Typherix, Typhim
For adults and children over 2 years travelling to at risk areas |
09.02.01.01 |
Polystyrene Sulphonate Resins Calcium Resonium® |
For oral or rectal administration |
09.02.01.01 |
Polystyrene Sulphonate Resins Resonium A® |
For oral or rectal administration |
13.09 |
Polytar® shampoo Coal tar solution 4% |
|
11.08.01 |
Polyvinyl alchohol 1.4% eye drops SnoTears® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
08.02.04 |
Pomalidomide Imnovid® |
|
08.01.05 |
Ponatinib Iclusig® |
|
03.05.02 |
Poractant Alfa Curosurf® |
Neonatal unit only |
05.02 |
Posaconazole (IV) Noxafil® |
|
05.02 |
Posaconazole (oral) Noxafil® |
|
11.99.99.99 |
Potassium Ascorbate 10% (Ascorbic acid) |
Unlicensed |
09.02.01.03 |
Potassium Bicarbonate |
Potassium bicarbonate 500 mg, potassium acid tartrate 300 mg, each tablet providing 6.5 mmol of K+.
NB these tablets do not contain chloride. |
20 |
Potassium canrenoate injection 200 mg in 10mL |
Unlicensed
Paediatrics only |
09.02.01.01 |
Potassium Chloride Kay-Cee-L® |
Potassium chloride 7.5% (1 mmol/mL each of K+ and Cl-) |
09.02.01.01 |
Potassium Chloride Sando-K® |
Potassium bicarbonate and chloride equivalent to potassium 470 mg (12 mmol of K+) and chloride 285 mg (8 mmol of Cl-) per tablet |
09.02.01.01 |
Potassium Chloride Slow-K® |
Avoid unless effervescent tablets or liquid preparations inappropriate |
09.02.02.01 |
Potassium Chloride and Glucose Intravenous Infusion |
|
09.02.02.01 |
Potassium Chloride and Sodium Chloride Intravenous Infusion |
|
09.02.02.01 |
Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion |
|
07.04.03 |
Potassium Citrate |
NHS England low value medicine
A prescription for treatment of mild cystitis should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
09.05.02.01 |
Potassium dihydrogen phosphate |
|
20 |
Potassium iodide capsules |
|
13.11 |
Potassium Permanganate Permitabs® |
For preparation of topical solution, potassium permanganate 400 mg (1 tablet)dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution |
13.11.06 |
Potassium Permanganate Permitabs® |
For preparation of topical solution, potassium permanganate 400 mg (1 tablet)dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution |
13.11.06 |
Potassium Permanganate Permitabs® |
For preparation of topical solution, potassium permanganate 400 mg (1 tablet)dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution |
19.20 |
Potassium permanganate tablets Permitabs® tablets for topical solution |
Information on restriction - Dermatology only.
One Permitabs solution tablet should be dissolved in four litres of water to produce a 0.01% (1 in 10 000) solution of potassium permanganate.
Medicines safety team request that Permitabs are always issued in full containers to ensure all safety warning information is available |
13.11.04 |
Povidone-Iodine Betadine® or Videne® |
Aqueous solution 10%, alcoholic solution 10% , sugical scrub 7.5%, powder spray 2.5% |
18 |
Pralidoxime chloride Protopam® |
|
04.09.01 |
Pramipexole |
NOT for restless legs syndrome.
Cost effecive brand for prescribing in primary care is Pipexus. |
02.09 |
Prasugrel Efient® |
Acute Coronary Syndromes with percutaneous coronary intervention. |
02.12 |
Pravastatin |
Prescribe generically |
01.05.02 |
Prednisolone |
Includes rectal foam, retention enema and suppositories |
06.03.02 |
Prednisolone |
Plain tablets are preferred for all indications. There is no conclusive evidence that the use of enteric-coated preparations of prednisolone reduces the risk of peptic ulceration (BNF) and absorption from EC tablets may be less predictable.
Soluble tablets are very HIGH COST (£52.75 for 30, June 2017 Drug Tariff). Plain tablets can be dispersed in water (unlicensed use). |
11.04.01 |
Prednisolone 0.5% eye drops Predsol ® |
|
11.04.01 |
Prednisolone 0.5% preservative free eye drops |
|
11.04.01 |
Prednisolone 1% eye drops Pred Forte® |
|
12.01.01 |
Prednisolone ear drops Predsol® |
|
04.02.03 |
Pregabalin |
|
04.07.03 |
Pregabalin |
Secondline if gabapentin effective but not tolerated. Pain Clinic, Diabetology, Neurology Consultant only in PHT. Refer to Chronic Pain Guidelines. |
A2.01 |
Pregestimil Lipil® |
On advice of secondary care only
Cows milk allergy with malabsorption |
15.02 |
Prilocaine Hydrochloride Citanest® |
|
15.02 |
Prilocaine Hydrochloride Prilotekal® |
Spinal anaesthesia in day surgery patients only |
15.02 |
Prilocaine Hydrochloride with Felypressin Citanest with Octapressin® |
|
05.04.01 |
Primaquine |
|
04.08.01 |
Primidone |
Note HIGH COST in primary care.
MHRA Advice on switching:
Category 1: ensure patient is maintained on a specific manufacturer's product. |
14.04 |
Priorix® |
Measles, Mumps and Rubella vaccine (live)
For use in routine immunisation programme at 1 year old and preschool booster |
08.01.05 |
Procarbazine |
|
04.06 |
Prochlorperazine |
|
04.06 |
Prochlorperazine Buccastem® |
|
04.09.02 |
Procyclidine |
|
04.09.02 |
Procyclidine |
|
18 |
Procyclidine |
Treatment of poisoning - dystonic reactions |
13.10.05 |
Proflavine Cream, BPC |
|
06.04.01.02 |
Progesterone Crinone® |
4% Gel
Secondary care intiated - see IVF protocol |
06.04.01.02 |
Progesterone Cyclogest® |
Under secondary care supervision - recurrent miscarriage (unlicensed) |
06.04.01.02 |
Progestogen (micronised) oral/ vaginal capsules Utrogestan ® |
Only 100mcg capsules are licensed for HRT
Can be administered orally or vaginally |
08.02.02 |
Prograf® Tacrolimus |
|
08.02.02 |
Prograf® Tacrolimus |
RED for renal indications |
05.04.01 |
Proguanil Hydrochloride Paludrine® |
Travel Prophylaxis - Private Prescription |
05.04.01 |
Proguanil Hydrochloride with Atovaquone Malarone® |
Travel Prophylaxis - Private Prescription |
05.04.01 |
Proguanil hydrochloride with chloroquine |
Travel prophylaxis - private prescription |
04.02.01 |
Promazine Hydrochloride |
|
03.04.01 |
Promethazine Phenergan® |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
04.06 |
Promethazine Hydrochloride Phenergan |
NHS England low value medication
A prescription for the treatment of travel sickness should not routinely be offered in primary care as the condition is appropriate for self-care. |
02.03.02 |
Propafenone |
|
11.03.01 |
Propamidine Isetionate Brolene® eye drops |
Acanthamoeba keratitis (unlicensed indication) |
15.01.01 |
Propofol Diprivan® |
|
02.04 |
Propranolol |
|
04.07.04.02 |
Propranolol |
|
20 |
Propylene glycol 40% w/w in aqueous cream |
Unlicensed special listed on BAD specials list 2018 |
13.04 |
Propylene glycol 40% w/w in Dermovate cream |
Included in BAD specials list 2014 |
20 |
Propylene glycol 50% w/w in water |
Unlicensed special listed on BAD specials list 2018 |
13.02.01 |
Propylene gycol 20% w/w in aqueous cream |
Included on BAD special list |
06.02.02 |
Propylthiouracil |
|
02.08.03 |
Protamine sulfate injection |
|
18 |
Protamine Sulphate |
Heparin overdose / reversal |
02.11 |
Prothrombin Complex Concentrate Octaplex® |
|
19.15 |
Protosan 30ml gel |
Cleansing, decontamination and moisturising of acute and chronic skin wounds, first and second degree burns. (impregnated with dialkylcarbamoyl chloride) |
19.15 |
Protosan 350ml bottle |
Single patient use, more cost effective and has a shelf life of 8 weeks once opened.
Wound irrigation solution containing Betaine which is gentle effective surfactant which penetrates, disturbs and removes biofilm and wound debris, and PHMB to help control bacterial levels on the wound. |
19.15 |
Protosan 40ml Pod |
Protonsan pods should be reserved for acute use only. |
11.07 |
Proxymetacaine unit dose eye drops Minims® |
|
01.06.07 |
Prucalopride Resolor® |
Refractory constipation in women only in line with NICE TA 211 |
03.10 |
Pseudoephedrine Hydrochloride Galpseud® |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
05.01.09 |
Pyrazinamide |
Oral solution 500mg in 5ml (unlicensed) for use in paediatrics only |
10.02.01 |
Pyridostigmine Bromide |
|
18 |
Pyridoxine 50mg/mL |
Neonatal unit - for seizures caused by inborn errors of metabolism.
Isoniazid poisoning |
09.06.02 |
Pyridoxine hydrochloride |
|
05.04.01 |
Pyrimethamine with Sulfadoxine Fansidar® |
|
04.02.01 |
Quetiapine |
Immediate release only |
04.02.01 |
Quetiapine XL |
Generic immediate release tablets are first line - refer to guidance from Solent NHS Trust and Southern Health NHS FT
Most cost effective brand in primary care is Sondate XL |
06.07.01 |
Quinagolide Norprolac® |
Hyperprolactinaemia - safer alternative to cabergoline |
10.02.02 |
Quinine bisulphate tablets |
For nocturnal cramps |
05.04.01 |
Quinine dihydrochloride |
Available from special order manufacturers or specialist importers |
05.04.01 |
Quinine sulfate |
|
13.02.01 |
QV® |
Suitable for twice daily use |
14.04 |
Rabies vaccine |
Private supply only |
08.03.04.02 |
Radium-223 dichloride Xofigo® |
|
06.04.01.01 |
Raloxifene Hydrochloride Evista® |
|
05.03.01 |
Raltegravir Isentress ® |
HIV infection only |
08.01.03 |
Raltitrexed Tomudex® |
|
02.05.05.01 |
Ramipril |
|
11.08.02 |
Ranibizumab Lucentis® |
|
01.03.01 |
Ranitidine |
Includes tablets, oral solution and injection
NHS England low value medication
A prescription for mild infrequent indegestion and heatburn should not routinely be offered in primary care as the condtion is appropriate for self-care |
02.06.03 |
Ranolazine Ranexa® |
|
04.09.01 |
Rasagiline |
|
10.01.04 |
Rasburicase Fasturtec® |
Oncology, Haematology and Crtical Care only |
13.08.01 |
Reflectant (Dundee) sunscreens |
coffee, coral pink, beige
Used to treat photosensitivity disorders where the patient is sensitive to visible light, most commonly solar urticaria and porphyrias, particularly erythropoietic protoporphyria.
Unlicensed specials on BAD list
|
08.01.05 |
Regorafenib Stivarga® |
|
05.03 |
Remdesivir |
For use as per EAMS criteria only for COVID19 |
15.01.04.03 |
Remifentanil |
Critical Care only |
09.06.07 |
Renavit® |
For use in renal dialysis patients only |
06.01.02.03 |
Repaglinide Prandin® |
Secondary Care initiated
Alternative to sulphonylurea in selected patients |
14.04 |
Repevax® |
Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
For use in routine immunisation programme - preschool booster |
03.04.02 |
Reslizumab Cinquaero® |
|
14.04 |
Revaxis® |
Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
For use in routine childhood vaccination programme - teenage booster |
05.03.05 |
Ribavirin |
RSV bronchiolitis - consultant paediatrician only |
08.03.04.01 |
Ribociclib Kisqali® |
Approved in accordance with the Cancer Drugs Fund and NICE TA496 in combination with an aromatase inhibitor for the treatment of postmenopausal woman with previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. |
05.01.09 |
Rifabutin Mycobutin® |
Mycobacterium avium prophylaxis only |
05.01.09 |
Rifampicin Rifadin® |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® |
|
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
|
05.01.09 |
Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® |
|
05.01.07 |
Rifaximin Targaxan® |
Hepatic encephalopathy, consultant hepatologist only |
05.03.01 |
Rilpivirine hydrochloride Edurant® |
HIV infection only |
05.03.01 |
Rilpivirine, emtrictabine and tenofovir alafenamide Odefsey® |
HIV infection only |
04.09.03 |
Riluzole |
|
13.05.03 |
Risankizumab Skyrizi® |
|
06.06.02 |
Risedronate sodium |
Second-line for Paget's disease |
06.06.02 |
Risedronate sodium |
Once weekly for osteoporosis |
04.02.01 |
Risperidone |
|
04.02.02 |
Risperidone Risperdal Consta® |
Southern Health NHS FT and Solent NHS Trust psychiatrists only |
05.03.01 |
Ritonavir Norvir® |
HIV infection only |
08.02.03 |
Rituximab MabThera®, Truxima® |
|
08.02.03 |
Rituximab MabThera® |
Lymphoma only. NHSE SSC 1434 |
10.01.03 |
Rituximab MabThera®, Truxima® |
For SLE refer to NHSE policy |
02.08.02 |
Rivaroxaban Xarelto® |
VTE following elective hip and knee replacement - FULL COURSE SUPPLIED BY HOSPITAL |
02.08.02 |
Rivaroxaban Xarelto® |
Stroke prevention in non-valvular AF
DVT treatment and secondary prevention
PE treatment and secondary prevention |
02.08.02 |
Rivaroxaban Xarelto® |
Post ACS with antiplatelet |
04.11 |
Rivastigmine |
Alzeimers Disease
Dementia associated with Parkinsons disease or Lewy bodies - Priorities Committee Policy Statement 25
Cost effective brand for prescribing in primary care is Alzest
|
04.07.04.01 |
Rizatriptan tablets, orodispersible tablets |
|
15.01.05 |
Rocuronium bromide |
|
03.03.03 |
Roflumilast Daxas® |
|
09.01.04 |
Romiplostim Nplate® |
|
04.09.01 |
Ropinirole |
Can be used for Parkinson's Disease, restless legs syndrome if initiated by Sleep Clinic or symptom control in renal palliative care (off-license). MR formulation may improve adherence
Cost effective brand for primary care is Spiroco or Ipinnia |
15.02 |
Ropivacaine Hydrochloride Naropin® |
|
02.12 |
Rosuvastatin |
Third-line only if other statins cannot be tolerated |
14.04 |
Rotavirus vaccine Rotarix® |
For use in routine immunisation programme at 8 weeks old and and 12 weeks old. |
04.09.01 |
Rotigotine Neupro® |
|
08.01.05 |
Rucaparib Rubraca® |
|
04.08.01 |
Rufinamide Inovelon® |
Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome - initiation by paediatric neurology specialist only.
MHRA advice on switching:
Category 2: need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
08.01.05 |
Ruxolitinib Jakavi® |
|
02.05.05.02 |
Sacubitril valsartan Entresto® |
Symptomatic chronic heart failure with reduced ejection fraction NICE TA 388 |
03.01.01.01 |
Salbutamol |
Nebuliser solution |
03.01.01.01 |
Salbutamol Easyhaler |
Cost-effective option when a dry powder device is required |
03.01.01.01 |
Salbutamol Ventolin® |
MDI / Accuhaler |
03.01.01.01 |
Salbutamol Asmasal Clickhaler® |
Dry powder |
03.01.01.01 |
Salbutamol Salamol®Easi-Breathe |
|
07.01.03 |
Salbutamol infusion unlicensed |
|
03.01.01.01 |
Salbutamol IV |
|
13.07 |
Salicylic acid 12% gel Salatac® |
NHS England low value medication
A prescription for the treatment of warts and verrucae should not routinely be offered in primary care as the condition is appropriate for self-care. |
13.07 |
Salicylic acid 16.7% with lactic scid 16.7% Salactol® |
NHS England low value medication
A prescription for the treatment of motion sickness should not routinely be offered in primary care as the condition is appropriate for self-care. |
13.05 |
salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream |
Included in BAD specials list 2014 |
13.07 |
Salicylic acid 26% Occlusal® |
NHS England low value medication
A prescription for the treatment of warts and verrucae should not routinely be offered in primary care as the condition is appropriate for self-care. |
13.04 |
Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate cream |
Included on BAD specials list 2014 |
03.01.01.01 |
Salmeterol |
MDI
Accuhaler
|
09.06.07 |
Sanatogen® A-Z Complete |
Adults only where a combination of vitamins and minerals is required.
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption. |
09.05.01.01 |
Sandocal-1000® |
Calcium 1g = 25mmol per tablet |
05.03.01 |
Saquinavir Invirase® |
HIV infection only |
10.01.03 |
Sarilumab Kevzara® |
For use in line with NICE TA485 |
13.05.02 |
Sebco® |
|
10.01.03 |
Secukinumab injection Cosentyx® |
|
13.05.03 |
Secukinumab injection Cosentyx® |
|
04.09.01 |
Selegiline Hydrochloride |
|
06.01.02.03 |
Semaglutide Ozempic® |
Once weekly injection for type 2 diabetes |
06.01.02.03 |
Semaglutide Rybelsus® |
For restricted use for patients where subcutaneous semaglutide would be considered an option but where the subcutaneous rote of administration is not tolerated or advisable
May be initiated on the advice of community specialist nurses. |
01.06.02 |
Senna |
Includes tablets and syrup
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
04.03.03 |
Sertraline |
First line agent in general population |
09.05.02.02 |
Sevelamer Carbonate Renvela® |
Red for renal dialysis patients |
09.05.02.02 |
Sevelamer Hydrochloride Renagel® |
Red for renal dialysis patients |
15.01.02 |
Sevoflurane |
|
02.05.01 |
Sildenafil Revatio® |
Pulmonary Hypertension in paediatrics |
07.04.05 |
Sildenafil |
First line for erectile dysfuntion
NHS prescribing unrestricted for generic |
13.02.02 |
Silicone Sterile barrier cream |
|
13.07 |
Silver nitrate 40% with potassium nitrate 60% AVOCA® |
|
13.07 |
Silver nitrate 95% with potassium nitrate 5% AVOCA® |
|
13.10.01.01 |
Silver Sulfadiazine cream Flamazine® |
|
01.01.01 |
Simeticone Infacol® |
NHS England low value medicine
A prescription for treatment of infant colic should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
A2.01 |
Similac Alimentum |
Cows Milk Protein Allergy
Extensively Hydrolysed Formula
First Choice Agent |
A2.01 |
Similac High Energy |
See faltering growth guideline |
03.09.02 |
Simple Linctus, BP |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
02.12 |
Simvastatin |
Prescribe generically |
13.02.02 |
Siopel® barrier cream |
|
08.02.04 |
Siponimod Mayzent |
|
08.02.02 |
Sirolimus Rapamune® |
Existing patients with shared care may continue to obtain supplies via GP. |
20 |
Sirolimus 0.1% in WSP |
Unlicensed special listed on BAD specials list 2018 |
20 |
Sirolimus 0.5% in WSP |
Unlicensed special listed on BAD specials list 2018 |
06.01.02.03 |
Sitagliptin Januvia® |
|
A2.01 |
SMA Alfamino |
Cows Milk Protein Allergy 2nd line
First line for anaphylactic reaction/severe reations
|
A2.01 |
SMA Alfamino ® |
Amino Acid Formula
First line for severe reactions/ anaphylactic reactions/ reactions to breast milk
Refer to secondary care |
A2.01 |
SMA Althera |
Extensively Hydrolysed Formulae - CMPA |
A2.01 |
SMA High Energy |
See faltering growth guidance |
A2.01 |
SMA Pro Gold Prem 2 |
Should not be initiated in primary care
Follow hospital discharge instructions
Ensure review at 6 months corrected age |
A2.01 |
SMA Pro High Energy® |
Energy dense formula |
09.03 |
SMOF lipid® |
|
09.05.02 |
Sodium acid phosphate 1mmol in 1ml |
Paediatrics only
Unlicensed special |
10.01.03 |
Sodium aurothiomalate Myocrisin® |
Manufacturer reports that this product is being discontinued in 2019 |
09.08.01 |
Sodium benzoate 2g in 10ml injection |
Unlicensed special
Paediatrics only |
09.02.01.03 |
Sodium Bicarbonate |
Sodium bicarbonate 500mg approx. 6 mmol each of Na+ and HCO3– |
09.02.02.01 |
Sodium Bicarbonate |
|
18 |
Sodium bicarbonate |
Treatment of poisoning |
12.01.03 |
Sodium bicarbonate ear drops |
NHS England low value medication
A prescription for the removal of earwax should not routinely be offered in primary care as the condition is appropriate for self-care. |
09.02.02.01 |
Sodium bicarbonate oral solution 8.4% 1mmol in 1ml |
Unlicensed special
Paediatrics only |
09.02.01.02 |
Sodium Chloride Slow Sodium® |
Sodium chloride 600 mg (approx. 10 mmol each of Na+ and Cl-) per modified release tablet. |
13.11.01 |
Sodium Chloride 0.9% |
|
09.02.01.02 |
Sodium chloride 29.2% oral solution |
Paediatrics only |
03.07 |
Sodium chloride 3% (Hypertonic) MucoClear® |
Paediatrics only – bronchiolitis |
11.08.01 |
Sodium Chloride 5% eye drops and ointment |
|
03.07 |
Sodium chloride 7% (Hypertonic) |
Cystic fibrosis - adults and children. Refer to Drug Tariff for products prescribable on FP10 |
09.02.02.01 |
Sodium Chloride and Glucose Intravenous Infusion |
|
09.02.02.01 |
Sodium chloride intravenous injection/infusion |
Green When used as a diluent or line flush
|
01.06.04 |
Sodium Citrate Relaxit, Micolette |
|
11.99.99.99 |
Sodium citrate preservative free |
Unlicensed |
03.03.01 |
Sodium Cromoglicate Intal® |
MDI |
11.04.02 |
Sodium cromoglicate 2% eye drops |
NHS England low value medication
A prescription for the treatment of mild to moderate hay fever should not routinely be offered in primary care as the condition is appropriate for self-care |
09.01.01.01 |
Sodium Feredetate Sytron® |
|
09.05.03 |
Sodium fluoride mouthwash 0.05% En-De-Kay® |
On formulary for mouthcare for patients undergoing chemotherapy and/or radiotherapy only.
Refer to PHT guidance on mouthcare for patients undergoing chemotherapy and/or radiotherapy.
NHS England low value medication
A prescription for high fluoride toothpaste/mouthwash should not routinely be offered in primary care as the condition is appropriate for self-care |
09.05.03 |
Sodium fluoride mouthwash 0.05% FluoriGard® |
Available as an alcohol-free formulation.
On formulary for mouthcare for patients undergoing chemotherapy and/or radiotherapy only.
Refer to PHT guidance on mouthcare for patients undergoing chemotherapy and/or radiotherapy.
NHS England low value medication
A prescription for high fluoride toothpaste/mouthwash should not routinely be offered in primary care as the condition is appropriate for self-care |
09.05.03 |
Sodium fluoride toothpaste Duraphat® |
2800ppm (0.619%) and 5000ppm (1.1%) sodium fluoride
Solent and Southern Health long stay inpatients only following dental assessment.
Patients receiving radiotherapy to the head and neck, following dental asessment (refer to PHT mouth care guidelines for patients undergoing chamotherapy and/or radiotherapy)
NHS England low value medication
A prescription for high fluoride toothpaste/mouthwash should not routinely be offered in primary care as the condition is appropriate for self-care |
05.01.07 |
Sodium fusidate Fucidin® |
|
13.10.01.02 |
Sodium fusidate 2% ointment Fucidin® |
|
11.08.01 |
Sodium hyaluronate 0.1% eye drops Hylo-Tear® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
11.08.01 |
sodium hyaluronate 0.15% eye drops Artelac Rebalance® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
11.08.01 |
Sodium hyaluronate 0.2% eye drops Hylo-Forte® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
11.08.01 |
Sodium hyaluronate 0.4% eye drops and unit dose eye drops Clinitas® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
11.08.02 |
Sodium hyaluronate 1% in 1ml Z-Hyalin® |
|
20 |
Sodium Hyaluronate 800mg/50mL (1.6%), Sodium Chondroitin Sulfate 1g/50mL (2%) iAluRil® |
Licensed as a medical device
Urology only |
11.08.01 |
Sodium hyaluronate with dexpanthenol 2% eye drops Hylo-Care® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care. |
01.06.02 |
Sodium hydrogen carbonate 0.5g/ sodium dihydrogen phosphate 0.68g Lecicarbon A® |
Gastroenterology or urogynaecology recommendation for chronic constipation in adults that has not been successfully managed with standard laxatives, particularly where there are problems with evacuation. |
13.11.04 |
Sodium Hypochorite Solution 1% Milton® |
|
18 |
Sodium nitrite |
Antidote for cyanide poisoning
Available as Nithiodote (Co-Packaged Sodium Nitrite 30 mg/mL Solution for Injection and Sodium Thiosulfate 250 mg/mL Solution for Injection) |
02.05.01 |
Sodium nitroprusside |
Critical Care Only |
09.08.01 |
Sodium phenylbutyrate 2g in 10ml |
Unlicensed |
01.06.02 |
Sodium Picosulfate |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
02.13 |
Sodium Tetradecyl Sulphate Fibro-Vein® |
|
18 |
Sodium thiosulfate |
Antidote for cyanide poisoning
Available as Nithiodote (Co-Packaged Sodium Nitrite 30 mg/mL Solution for Injection and Sodium Thiosulfate 250 mg/mL Solution for Injection) |
20 |
Sodium thiosulfate |
Calciphylaxis |
04.02.03 |
Sodium valproate |
|
04.08.01 |
Sodium Valproate |
Includes tablets, MR tablets and liquid
MHRA advice on switching:
Category 2 - need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
04.08.01 |
Sodium Valproate injection |
|
09.02.01.01 |
Sodium zirconium cyclosilicate Lokelma® |
Secondary care prescribing only as PAS pricing |
05.03.03.02 |
Sofosbuvir Sovaldi® |
|
05.03.03.02 |
Sofosbuvir/velpatasvir Epclusa® |
|
05.03.03.02 |
sofosbuvir/velpatasvir/voxilaprevir Vosevi® |
|
19.01 |
Softpore 10cm x 10cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
19.01 |
Softpore 10cm x 15cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
19.01 |
Softpore 10cm x 20cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
19.01 |
Softpore 10cm x 25cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
19.01 |
Softpore 10cm x 30cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
19.01 |
Softpore 6cm x 7cm |
Not to be used on fragile skin. For minor superficial wounds where all that is required is protection from friction. can be used post-op which can stay in place for 3-5 days. |
07.04.02 |
Solifenacin Vesicare® |
|
06.05.01 |
Somatropin Injection |
|
08.01.05 |
Sorafenib Nexavar® |
|
06.01.02.03 |
Sotagliflozin |
For use by the hospital diabetes team only |
02.04 |
Sotalol |
|
07.03.03 |
Spermicidal Contraceptives Gygel gel |
To be used in conjunction with another method |
02.02.03 |
Spironolactone 50mg in 5ml |
Unlicensed special listed in Drug Tariff
Paediatrics only |
02.02.03 |
Spironolactone tablets |
|
13.02.02 |
Sprilon® spray |
|
05.03.01 |
Stavudine Zerit® |
HIV infection only |
01.06.01 |
Sterculia Normacol® |
NHS England low value medication
A prescription for infrequent constipation should not routinely be offered in primary care as the condtion is appropriate for self-care |
09.06.04 |
Stexerol-D3® 25,000 units |
Colecalciferol 25,000 units per tablet
Tablets can be swallowed whole or crushed. |
09.06.04 |
Stexerol-D3® 1,000 units |
Colecalciferol 1,000 units per tablet
Tablets can be swallowed whole or crushed. |
04.08.01 |
Stiripentol Diacomit® |
For Adults a shared care guideline is awaited
For paediatric patients, Stiripentol is Amber Initiated |
01.08 |
Stoma Care |
Products will be recommended by stoma care nurses |
02.10.02 |
Streptokinase |
Information on restriction - CCU, A&E and Surgery only
|
01.03.03 |
Sucralfate |
Includes tablets and suspension |
20 |
Sucralfate 4% in emulsifying ointment |
Unlicensed special listed on BAD specials list 2018 |
09.05.02.02 |
sucroferric oxyhydroxide Velphoro® |
For management of hyperphosphataemia in adult patients on dialysis only. |
13.02.02 |
Sudocrem® cream |
NHS England low value medication
A prescription for the treatment of nappy rash should not routinely be offered in primary care as the condition is appropriate for self-care |
15.01.06 |
Sugammadex Bridion® |
For emergency reversal of rocuronium following failed intubation - refer to PHT Drug Therapy Guideline |
01.05.01 |
Sulfasalazine |
Includes tablets and suspension |
10.01.03 |
Sulfasalazine EC Salazopyrin EN-Tabs® |
Initiation by rheumatologist only
Salazopyrin brand most cost effective in primary care |
04.02.01 |
Sulpiride |
|
04.07.04.01 |
Sumatriptan |
Note 50mg tablets available in PHT to aid diagnosis only NOT for routine treatment
NHS England low value medicine
A prescription for infrequent mild migraine should not routinely be offered in primary care as the condition is suitable for self-care. |
08.01.05 |
Sunitinib Sutent® |
|
13.08.01 |
Sunsense® Ultra |
NHS England low value medicine
A prescription for sun protection should not routinely be offered in primary care as this is suitable for self-care.
Sun protection may be prescribed as per ACBS recommendations: Approved for skin protection against UV radiation in abnormal cutaneous photosensitivity. This includes genetic disorders, photodermatoses, vitiligo from radiotherapy and chronic or recurrent herpes simplex labialis. |
09.03 |
Supplementary Preparations for intravenous nutrition |
|
19.08 |
Suprasorb A 10cm x 10cm |
Calcium alginate primary dressing for use in shallow, moist wounds. for management of moderatley or heavily exuding wounds.
secondary dressings are required to support the alginate in situ and maintain a moist environment. |
19.08 |
Suprasorb A 5cm x 5cm |
Calcium alginate primary dressing for use in shallow, moist wounds. for management of moderatley or heavily exuding wounds.
secondary dressings are required to support the alginate in situ and maintain a moist environment. |
19.08 |
Suprasorb A Rope 2g (30cm) |
For exudate management and wound healing of large open cavity wounds. |
19.15 |
Suprasorb X + PHMB 14cm x 20cm |
Light to moderately exuding wounds, superficial and deep, critically colonised and infected wounds. Bio-cellulose dressing impregnated with broad-spectrum antimicrobial (PMBH polyhexamethylene biguanide 0.3%) can be effective if the wound is infected and painful. |
19.15 |
Suprasorb X + PHMB 2cm x 21cm |
Light to moderately exuding wounds, superficial and deep, critically colonised and infected wounds. Bio-cellulose dressing impregnated with broad-spectrum antimicrobial (PMBH polyhexamethylene biguanide 0.3%) can be effective if the wound is infected and painful. |
19.15 |
Suprasorb X + PHMB 5cm x 5cm |
Light to moderately exuding wounds, superficial and deep, critically colonised and infected wounds. Bio-cellulose dressing impregnated with broad-spectrum antimicrobial (PMBH polyhexamethylene biguanide 0.3%) can be effective if the wound is infected and painful. |
19.15 |
Suprasorb X + PHMB 9cm x 9cm |
Light to moderately exuding wounds, superficial and deep, critically colonised and infected wounds. Bio-cellulose dressing impregnated with broad-spectrum antimicrobial (PMBH polyhexamethylene biguanide 0.3%) can be effective if the wound is infected and painful. |
15.01.05 |
Suxamethonium chloride |
|
13.05.03 |
Tacrolimus Protopic® |
0.03% and 0.1%
Second-line after steroids for moderate to severe atopic eczema - NICE TA 82. Not for children under 2. Age 2-16 use 0.03% only |
20 |
Tacrolimus 0.1% and 0.03% in Orabase |
Used for ulcerative and erosive inflammatory skin disease including around stomas.
Unlicensed special on BAD list.
|
07.04.05 |
Tadalafil Cialis® |
Second line if a longer duration of action is needed |
11.06 |
Tafluprost (Preservative Free) 15micrograms/ml Saflutan® |
|
11.06 |
Tafluprost and Timolol Taptiqom® |
Preservative-free drops in single dose containers.
Only for use where preservative-free combination treatment is indicated. |
20 |
TALC BP purified sterile |
For talc pleurodesis - refer to PHT Drug Therapy Guideline |
08.02.04 |
Talimogene laherparepvac Imlygic® |
|
08.01.05 |
Talimogene laherparepvec Imlygic® |
|
08.03.04.01 |
Tamoxifen |
|
07.04.01 |
Tamsulosin hydrochloride |
|
04.07.02 |
Tapentadol |
For paediatric in-patient use only |
04.07.02 |
Tapentadol Palexia® |
Acute pain team only as alternative to oxycodone and only if first-line morphne not tolerated. To be supplied as TTO only if prescribed by acute pain team; not to be continued in primary care
|
04.07.02 |
Tapentadol Palexia®SR |
Severe chronic pain, secondline option only when morphine has not provided adequate pain control or cannot be tolerated
|
13.05.02 |
Tazarotene Zorac® |
0.05% and 0.1% gel |
08.01.03 |
Tegafur with Uracil Teysuno® |
|
05.01.07 |
Teicoplanin Targocid® |
|
04.01.01 |
Temazepam |
Short term use only |
05.01.01.02 |
Temocillin Negaban® |
On microbiology advice |
08.01.05 |
Temozolomide |
|
02.10.02 |
Tenecteplase Metalyse® |
Information on restriction - For myocardial infarction only - use alteplase for PE
Information on restriction - For recanalization before planned thrombectomy in patients requiring transfer to specialist centre without medical escort
|
05.03.01 |
Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla® |
HIV infection only |
05.03.01 |
Tenofovir alafenamide, elvitegravir, cobicistat & emtricitabine Genvoya® |
HIV infection only |
05.03.01 |
Tenofovir and Emtricitabine Truvada® |
HIV infection only |
05.03.01 |
Tenofovir Disproxil Viread® |
|
05.03.01 |
Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild® |
HIV infection only |
05.02 |
Terbinafine |
Dermatology use only in secondary care. |
13.10.02 |
Terbinafine 1% cream |
NHSE low value medication
A prescription for the treatment of ringworm or athlets foot should not routinely be offered in primary care as the condition is appropriate for self-care |
03.01.01.01 |
Terbutaline |
Turbohaler (DPI)
Nebules |
06.06.01 |
Teriparatide Forsteo® |
Secondary Care Only |
06.05.02 |
Terlipressin Glypressin® |
Secondary Care only |
06.04.02 |
Testogestone gel Testavan® |
|
06.04.02 |
Testosterone and Esters Testogel® |
|
06.04.02 |
Testosterone and Esters |
Alternative injection for use by paediatrics if Sustanon is unavailable
Secondary care initiated |
06.04.02 |
Testosterone gel Tostran® |
|
06.04.02 |
Testosterone injection Sustanon 250® |
|
06.04.02 |
Testosterone undecanoate Nebido® |
3 monthly IM - alternative to sustanon
|
14.05.02 |
Tetanus immunoglobulin |
|
04.09.03 |
Tetrabenazine |
|
15.02 |
Tetracaine (Amethocaine) Ametop® |
|
11.07 |
Tetracaine unit dose eye drops Minims® |
0.5% and 1% |
06.05.01 |
Tetracosactide Synacthen® |
Secondary care only |
05.01.03 |
Tetracycline |
Restricted prescribing as per Microguide or NICE prescribing guidance |
03.07 |
Tezacaftor/Ivacaftor Symkevi® |
NHS England commissioning statement Cystic Fibrosis Modular Therapies 190137P |
08.02.04 |
Thalidomide Celgene® |
|
03.01.03 |
Theophylline Nuelin® SA |
Prescribe by brand name |
03.01.03 |
Theophylline Uniphyllin® Continus |
Prescribe by brand name |
09.06.02 |
Thiamine |
|
A2.05.02 |
Thick and Easy® |
|
15.01.01 |
Thiopental sodium |
|
08.01.01 |
Thiotepa |
|
A2.05.02 |
Thixo-D® |
|
06.05.01 |
Thyrotropin Alfa Thyrogen® |
Secondary care only |
04.08.01 |
Tiagabine Gabitril® |
MHRA advice on switching:
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors. |
06.04.01.01 |
Tibolone Livial® |
Short term treatment of oestrogen deficiency |
02.09 |
Ticagrelor Brilique® |
In combination with aspirin for prevention of atherothrombotic events in ACS - 90mg bd for up to 12 months
In combination with aspirin in people with a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event - 60mg bd for up to 3 years |
05.01.03 |
Tigecycline Tygacil® |
Microbiology recommendation only |
13.05.03 |
Tildrakizumab Ilumetri® |
|
13.04 |
Timodine® |
Hydrocortisone 0.5%, nystatin 100 000 units/g |
11.06 |
Timolol 0.25% and 0.5% |
Eye dops, eye gel, preservative free unit dose eye drops |
05.01.11 |
Tinidazole Fasigyn® |
GUM and H Pylori eradication only |
02.08.01 |
Tinzaparin |
Information on restriction - haemodialysis only
|
08.01.03 |
Tioguanine |
|
03.01.02 |
Tiotropium Spiriva® |
Handihaler and Respimat (Refer to COPD guidelines) |
03.01.04 |
Tiotropium & olodaterol® Spiolto Respimat |
LABA + LAMA refer to COPD guidelines |
05.03.01 |
Tipranavir Aptivus® |
HIV infection only |
08.01.05 |
Tisagenlecleucel Kymriah® |
|
08.01.05 |
Tivozanib Fotivda® |
|
10.02.02 |
Tizanidine tablets |
Spasticity - secondline after baclofen |
05.01.04 |
Tobramycin |
|
05.01.04 |
Tobramycin Bramitob® |
Cystic fibrosis only - cycle 28 days on treatment, 28 days off. |
05.01.04 |
Tobramycin inhaler TOBI Podhaler® |
Pseudomonas lung infection in cystic fibrosis |
10.01.03 |
Tocilizumab RoActemra® |
|
10.01.03 |
Tofacitinib Xeljanz® |
|
02.05.01 |
Tolazoline |
Paediatrics only |
07.04.02 |
Tolterodine |
|
06.05.02 |
Tolvaptan Samsca® |
Proven SIADH with failure of fluid restriction. Consultant endocrinologist only to diagnose and prescribe. Short term use only - not for TTO.
Hypomatraemia due to SIADH in patients receving cancer chemotherapy- refer to NHSE Comsssioining policy and PHT Drug Therapy Guideline |
06.05.02 |
Tolvaptan Jinarc® |
Secondary Care only
Autosomal dominant polycystic kidney disease |
04.07.04.02 |
Topiramate |
|
04.08.01 |
Topiramate |
MHRA advice on switching:
Category 2 - need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
08.01.05 |
Topotecan |
|
08.01.05 |
Topotecan Hycamtin® |
|
08.01.05 |
Trabectedin Yondelis® |
|
04.07.02 |
Tramadol |
Not first line - refer to Chronic Pain Guidelines.
Immediate release preferred.
Preferred brand of MR tablets in primary care is Tramulief (twice daily dosage) - prescribe by brand name. |
04.07.02 |
Tramadol injection |
|
08.01.05 |
Trametinib Mekinist® |
|
02.11 |
Tranexamic Acid |
|
02.11 |
Tranexamic acid 250mg in 5ml |
Paediatrics only
Unlicensed special listed in Drug Tariff |
04.03.02 |
Tranylcypromine |
Psychiatry only
Note HIGH COST in primary care |
08.01.05 |
Trastuzumab Herceptin® |
Subcutaneous injection licensed for breast cancer only. |
08.01.05 |
Trastuzumab emtansine Kadcyla® |
|
11.06 |
Travoprost Travatan® |
|
11.06 |
Travoprost with Timolol DuoTrav® |
|
04.03.01 |
Trazodone |
|
03.02 |
Trelegy DPI |
Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed. More cost-effective than using separate ICS/LABA + LAMA.
Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent to 62.5 micrograms umeclidinium and 25 micrograms vilanterol (as trifenatate).
Dose: 1 inhalation once daily |
08.01.01 |
Treosulfan |
|
08.01.05 |
Tretinoin |
|
06.03.02 |
Triamcinolone Kenalog® |
|
20 |
Triamcinolone 0.1% in Orabase |
Used for ulcerative and erosive inflammatory skin disease including around stomas.
Unlicensed special on BAD list. |
10.01.02.02 |
Triamcinolone acetonide |
Adcortyl Intra-articular/Intradermal Injection 10 mg/ml
Kenalog Intra-articular / Intramuscular Injection 40mg/ml |
10.01.02.02 |
Triamcinolone hexacetonide 20mg per ml |
For intra-articular and peri-articular injection |
12.01.01 |
Triamcinolone with Antibacterial Otocomb Otic® |
Unlicensed in the UK. For ENT clinic use only.
5g tube contains: Triamcinolone Acetonide 1mg/g Gramicidin 0.25mg/g Neomycin Base (as sulphate) 2.5mg/g Nystatin in Plastibase 100,000units/g |
06.01.01.03 |
TriCare pen needles |
|
13.07 |
Trichloroacetic Acid |
Dermatology Only |
13.01 |
Trichloroacetic acid 90% w/v |
Included in BAD specials list 2014 |
13.11.05 |
Triclosan 2% Ster-Zac Bath Concentrate® |
|
04.02.01 |
Trifluoperazine |
|
11.03.03 |
Trifluorothymidine 1% |
Unlicensed - ophthalmology only |
08.01.03 |
Trifluridine-tiparicil tablets Lonsurf® |
Note NICE TA 669 Trifluridine-tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies states that this drug is not recommended for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more systemic treatment regimens |
04.09.02 |
Trihexyphenidyl Benzhexol |
|
03.02 |
Trimbow MDI |
Beclometasone/formoterol and glycopyrronium combined inhaler.
Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide).
Dose: 2 inhalations twice daily |
05.01.08 |
Trimethoprim |
|
13.04 |
Trimovate® |
Clobetasone butyrate 0.05%, oxytetracycline 3% (as calcium salt), nystatin 100 000 units/g, |
06.07.02 |
Triptorelin |
|
08.03.04.02 |
Triptorelin Decapeptyl® |
|
20 |
TROMETAMOL (THAM) 125ML Injection 3.6% (0.3M) |
Paediatric Use Only |
11.05 |
Tropicamide eye drops and unit dose eye drops |
0.5 % and 1% eye drops and preservative-free unit dose eye drops (Minims) |
06.01.01.03 |
TRUEplus Lancets |
|
06.01.06 |
TrueYou® |
Category 1 preferred |
14.04 |
Typhoid Live Oral vaccine Vivotif® |
For adults and children over 6 years travelling to at risk areas |
07.03.05 |
Ulipristal EllaOne® |
Second line on days 4 and 5 post UPSI if IUD unsuitable/not acceptable |
19.23 |
Ultra Lite 10cm x 4.5cm |
Bandage should be used as an alternative to K-Lite where there are symptoms of, or identified arterial disease present in the lower leg. |
19.23 |
Ultra Soft 10cm x 3.5cm |
Sub compression padding bandage used to protect the limb and for shaping if required. |
03.01.02 |
Umeclidinium Incruse Ellipta® |
Refer to COPD guidelines |
03.01.04 |
Umeclidinium & vilanterol Anoro Ellipta® |
LABA+LAMA. Refer to COPD guidelines |
01.07.02 |
Uniroid HC |
More cost effective than Proctosedyl. Includes ointment and suppositories
NHS England low value medicine
A prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment |
10.01.03 |
Upadacitinib Rinvoq® |
|
19.20 |
UrgoStart® |
There are 5 formats of the dressing and each comes in different sizes: UrgoStart Contact Layer, UrgoStart Non-Adhesive, UrgoStart Plus Pad, UrgoStart Border and UrgoStart Plus Border. |
02.10.02 |
Urokinase |
Information on restriction - Only for clearing blocked catheters
|
07.04 |
Uromune® |
For prescribing on a named patient basis by Mr Hall, Mrs Lavan and Miss Burton only |
01.09.01 |
Ursodeoxycholic acid |
Includes capsules, tablets and suspension |
01.05.03 |
Ustekinumab Stelara® |
|
10.01.03 |
Ustekinumab |
|
13.05.03 |
Ustekinumab injection Stelara® |
|
13.08.01 |
Uvistat® |
NHS England low value medicine
A prescription for sun protection should not routinely be offered in primary care as this is suitable for self-care.
Sun protection may be prescribed as per ACBS recommendations: Approved for skin protection against UV radiation in abnormal cutaneous photosensitivity. This includes genetic disorders, photodermatoses, vitiligo from radiotherapy and chronic or recurrent herpes simplex labialis. |
07.02.01 |
Vaginal moisturisers |
Replens MD, Yes, Sylk - refer to Drug Tariff for products prescribable on FP10 |
05.03.02.01 |
Valaciclovir |
Second line. Use in secondary care restricted to GUM and Haematology |
05.03.02.02 |
Valganciclovir Valcyte® |
For CMV treatment only |
04.02.03 |
Valproic Acid Depakote® |
|
02.05.05.02 |
Valsartan |
Cardiology only post-MI for patients intolerant of ACEI strictly in accordance with MI pathway |
05.01.07 |
Vancomycin Capsules |
C. difficle treatment |
05.01.07 |
Vancomycin |
|
11.03.01 |
Vancomycin intravitreal injection |
Unlicensed |
04.10.02 |
Varenicline Champix® |
Option for adults as part of smoking cessation programme |
14.04 |
Varicella Zoster vaccine Zostavax® |
National programme for adults aged 70 |
14.05.02 |
Varicella-Zoster immunoglobulin |
|
06.05.02 |
Vasopressin (argipressin) |
Secondary Care only |
15.01.05 |
Vecuronium bromide Norcuron® |
|
01.05.03 |
Vedolizumab Entyvio® |
Moderately to severely active ulcerative colitis NICE TA 342, moderately to severely active Crohns disease NICE TA 352 |
08.01.05 |
Vemurafenib Zelboraf® |
|
08.01.05 |
Venetoclax |
In line with NICE TA487 |
04.03.04 |
Venlafaxine |
Only after adequate trial of two alternative antidepressants. Not for patients with heart disease, including hypertension. Refer to mental health provider guidelines.
Prescribe as immediate release if possible. Most cost effective brand for modified release in primary care is Vensir XL Capsules |
02.06.02 |
Verapamil |
|
02.06.02 |
Verapamil Hydrochloride Securon® SR |
|
02.06.02 |
Verapamil Hydrochloride Half Securon® SR |
|
02.06.02 |
Verapamil Hydrochloride Univer® |
|
11.08.02 |
Verteporfin Visudyne® |
|
04.08.01 |
Vigabatrin Sabril® |
Refractory epilepsy only. Includes tablets and sachets.
MHRA advice on switching:
Category 3: usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific concerns, such as patient anxiety and risk of confusion or dosing errors |
08.01.04 |
Vinblastine Sulphate |
|
08.01.04 |
Vincristine Sulphate |
|
08.01.04 |
Vindesine Sulphate Eldisine® |
|
08.01.04 |
Vinorelbine |
|
08.01.04 |
Vinorelbine Navelbine® |
|
09.06.07 |
Vitamin and mineral supplements Forceval Soluble® |
Only for patients with swallowing difficulties or being tube fed and who need a multivitamin and mineral supplement on advice from a dietician.
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption.
|
09.06.07 |
Vitamin and mineral supplements Ketovite® |
Only on advice from dietetics
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption.
|
09.06.02 |
Vitamin B complex Vigranon B® |
NHS blacklisted - not to be prescribed on FP10. |
09.06.02 |
Vitamin B Tablets, Compound Strong |
NHS England low value medication
For medically diagnosed eficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption.
Malnutrition including alcoholism. |
09.06.01 |
Vitamins A and D |
Vitamin A 4000 units, vitamin D 400 units (10 micrograms) per capusle.
May be difficult to obtain. |
09.06.07 |
Vitamins capsules |
NHS England low value medication
For medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery which results in malabsorption. |
A2.05.02 |
Vitaquick® |
|
03.01.05 |
Volumatic® |
|
05.02 |
Voriconazole Vfend® |
|
04.03.03 |
Vortioxetine Brintellix® |
Major depressive episodes in adults NICE TA 367 |
02.08.02 |
Warfarin |
|
02.08.02 |
Warfarin 5mg in 5ml |
Paediatrics only |
09.02.02.01 |
Water for Injection |
|
06.01.06 |
Wavesense Jazz® |
Category 1 preferred |
13.02.01 |
White Soft Paraffin BP |
|
11.08.01 |
White soft paraffin/liquid paraffin eye ointment Hylo night®, Lacri-Lube® |
NHS England low value medication
A prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care.
VitA-POS is now marketed as HYLO NIGHT |
12.02.02 |
Xylometazoline nasal drops Otrivine® |
NHS England low value medicine
A prescription for coughs, colds and nasal congestion should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment. |
14.04 |
Yellow fever vaccine (Live) |
Designated centres only |
13.02.01 |
Yellow Soft Paraffin BP |
|
05.03.04 |
Zanamivir inhalation Relenza® |
|
05.03.04 |
Zanamivir Injection |
Refer to PHT Microguide |
13.02.01 |
Zerobase® |
Lower cost alternative to Diprobase |
13.02.01 |
Zerocream® |
Lower cost alternative to E45 cream |
13.02.01 |
Zerodouble® Gel |
Lower cost alternative to Doublebase ge |
13.02.01 |
Zeroguent® |
Lower cost alternative to Unguentum M |
13.02.01 |
Zeroveen® |
Lower cost alternative to Aveeno cream |
19.11 |
Zetuvit E Sterile 10cm x 10cm |
Absorbent and protective. Used as a secondary dressing. NB Community nurses can obtain Surgipads from central stores. |
19.11 |
Zetuvit E Sterile 10cm x 20cm |
Absorbent and protective. Used as a secondary dressing. NB Community nurses can obtain Surgipads from central stores. |
19.11 |
Zetuvit E Sterile 20cm x 20cm |
Absorbent and protective. Used as a secondary dressing. NB Community nurses can obtain Surgipads from central stores. |
19.11 |
Zetuvit E Sterile 20cm x 40cm |
Absorbent and protective. Used as a secondary dressing. NB Community nurses can obtain Surgipads from central stores. |
05.03.01 |
Zidovudine Retrovir® |
HIV infection only |
05.03.01 |
Zidovudine and Lamivudine |
HIV infection only |
13.02.02 |
Zinc and Caster Oil Ointment BP |
|
13.05.01 |
Zinc oxide 15% w/w and ichthammol 1% w/w in YSP |
Unlicensed special on BAD list and in Drug Tariff
|
09.05.04 |
Zinc Sulphate Solvazinc® |
|
06.06.02 |
Zoledronic Acid |
Annual infusion for osteoporosis
Paget's disease |
06.06.02 |
Zoledronic Acid |
Oncology only - for symptomatic skeletal events in hormone-refractory prostate cancer.
Oncology only - for adjuvant treatment of post-menopausal breast cancer (off-licence)
Palliative care |
04.07.04.01 |
Zolmitriptan |
If orodispersible tablets are required prescribe 2.5mg strength |
04.01.01 |
Zolpidem |
Short term use only |
04.08.01 |
Zonisamide Zonegran® |
Oral suspension 2mg in 1ml (unlicensed) - paediatrics only
MHRA advice on switching:
Category 2 - need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
04.01.01 |
Zopiclone |
Short term use only |
04.02.01 |
Zuclopenthixol Clopixol® |
|
04.02.01 |
Zuclopenthixol Acetate Clopixol Acuphase® |
Psychiatry only |
04.02.02 |
Zuclopenthixol Decanoate Clopixol® |
Psychiatry only |
04.02.02 |
Zuclopenthixol Decanoate Clopixol® Conc. |
Psychiatry only |